Document:

Exhibit
10.9

REDACTED

Certain
identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and
(ii) would likely cause competitive harm if publicly disclosed.

 

DATED:
15 February 2019

 

 

FRAMEWORK
PARTNERING AGREEMENT

 

 

BETWEEN

 

COALITION
FOR EPIDEMIC

 

PREPAREDNESS
INNOVATIONS

 

AND

 

CUREVAC
AG

 

Award Ref:

 

(Award Ref:       )

 

 

    

     

    

 

	 	CONTENTS	 
	Clause	 	Page
	 	 	 
	1.	DEFINITIONS AND INTERPRETATION
	2
	2.	PROJECT OBJECTIVES 	12
	3.	PROJECT FUNDING 	12
	4.	PROJECT, STANDARDS AND
RECORDS MANAGEMENT 	15
	5.	PROJECT MANAGEMENT AND
OVERSIGHT 	16
	6.	IPDP 	17
	7.	PARTNER OBLIGATIONS 	17
	8.	OUTBREAK AND RISK OF OUTBREAK
IN THE FIELD 	22
	9.	CLINICAL TRIALS	24
	10.	COLLABORATORS AND SUB-CONTRACTORS	26
	11.	PUBLIC HEALTH LICENSE 	27
	12.	CONDITIONS PRECEDENT AND
EXERCISE OF THE PUBLIC HEALTH LICENSE 	28
	13.	COMMERCIAL BENEFITS ARISING
FROM COMMERCIAL USE 	31
	14.	BACKGROUND TECHNOLOGY AND
PROJECT TECHNOLOGY 	31
	15.	PROJECT TECHNOLOGY –
EXPLOITATION 	32
	16.	ANNOUNCEMENTS AND PUBLICATIONS
	33
	17.	CONFIDENTIALITY 	33
	18.	WARRANTIES, LIABILITY AND
INSURANCE 	34
	19.	TERM, TERMINATION AND EFFECTS
OF TERMINATION 	38
	20.	EFFECTS OF TERMINATION
WHERE THE PARTNER IS THE DEFAULTING PARTY OR WHERE TERMINATION IS PURSUANT TO CLAUSE 19.3	39
	21.	GENERAL 	41
	22.	DISPUTE RESOLUTION, GOVERNING
LAW AND JURISDICTION 	44
	Schedule 1
Template Work Package Statement 	47
	Schedule 2
Partner Contribution 	54
	Schedule 3
Background Technology 	55
	Schedule 4
CEPI Funding and Project Budget 	56
	Schedule 5
Work Package Statements 	58
	Schedule 6
IPDP 	60
	Schedule 7
Cost of Goods Sold Formula 	61
	Schedule 8
Template Financial Summary and Reporting Form 	62
	Schedule 9
Semi-Annually Report Template 	79
	Schedule 10
CEPI Policies 	84
	Schedule 11
Team Charter 	86
	Schedule 12
Disclosure Letter 	87
	Schedule 13
Partner Funder Requirements 	88

 

    

     

    

 

 

THIS
AGREEMENT is made the                          
15th day of February                                 2019
(the “Effective Date”),

 

BETWEEN:

 

		1.	COALITION
                                         FOR EPIDEMIC PREPAREDNESS INNOVATIONS,
                                         a not-for-profit international association existing under Norwegian law with address
                                         at Marcus Thranesgate 2, PO Box 123 Torshov, N-0412 Oslo, Norway (“CEPI”);
                                         and

 

		2.	CUREVAC
                                         AG, a German corporation with address
                                         at Paul-Ehrlich-Strasse 15, 72076 Tübingen (the “Partner”).

 

WHEREAS:

 

		A.	CEPI
                                         is a public-private not-for-profit coalition including civil and philanthropic organizations,
                                         established: (i) to finance, coordinate and support the development of new vaccine platform
                                         technologies and new vaccines to prevent and contain infectious disease epidemics; (ii)
                                         working with its partners and relevant government agencies to ensure that vaccines developed
                                         are provided on an equitable basis to all populations who need them; and (iii) to ensure
                                         adequate stockpiles and manufacturing capacity of vaccines and vaccine platforms developed
                                         for epidemic situations.

 

		B.	The
                                         Partner has applied to CEPI under call “CfP2: Platform Technologies to enable rapid
                                         vaccine development for epidemic prone infections” for funding to undertake a project
                                         entitled “Rapid Response mRNA Vaccine Platform for Epidemic Preparedness”
                                         led by   [*****], of the Partner.

 

		C.	Partner
                                         is a biopharmaceutical company that is a pioneer and technology leader in messenger ribonucleic
                                         acid (“mRNA”) based vaccination approaches. Partner Controls intellectual
                                         property rights regarding the development and manufacture of mRNA based products, including
                                         manufacturing know-how licensed from Tesla Grohmann Automation GmbH (“TGA”).
                                         The manufacturing know-how licensed from TGA is targeted at establishing an automated
                                         manufacturing platform. Partner is interested to make its intellectual property available
                                         to further develop under this Agreement, including the TGA know-how for an automated
                                         manufacturing platform for the manufacture of mRNA-based products (the Platform, as defined
                                         below).

 

		D.	This
                                         Agreement sets out the terms and conditions governing the performance of the project,
                                         funding of the project and how the results of the project will be used to further CEPI’s
                                         mission.

 

    1

     

    

 

IT
IS AGREED as follows:

 

		1.	DEFINITIONS
                                         AND INTERPRETATION

 

		1.1	In
                                         this Agreement the following words have the meaning given below or given to them in relevant
                                         Clauses of this Agreement:

 

		1.1.1.	“Additional
                                         Work Package” means a Work Package of work under the Project to be agreed between
                                         the Parties from time to time in addition to those agreed upon on the Effective Date,
                                         and funded by CEPI which may be related to Products;

 

		1.1.2.	“Additional
                                         Work Package Statements” means the statement of activities, timeline, Partner
                                         Contribution, Milestones, Milestone Dates, Additional Work Package budget and payment
                                         schedule for a particular Additional Work Package agreed between the Parties. The template
                                         for Work Package Statements is the same as that for Additional Work Package Statements
                                         and is attached at Schedule 1;

 

		1.1.3.	“Affiliate”
                                         means any corporation or other business entity controlled by, controlling or under common
                                         control with the relevant Party. “control”, “controlled” and
                                         “controlling” for purposes of this definition shall mean: (i) direct or indirect
                                         beneficial ownership of fifty percent (50%) or more of the voting interest in an entity;
                                         or (ii) possession, directly or indirectly, of the power to direct or cause the direction
                                         of the management or policies of that entity (whether through ownership of securities
                                         or other ownership interests, by contract or otherwise). Regarding the Partner, Affiliate
                                         shall not include Mr. Hopp and dievini Hopp BioTech holding GmbH & Co. KG and/or
                                         any other entity controlled by Mr. Hopp and/or dievini Hopp Bio Tech holding GmbH &
                                         Co. KG;

 

		1.1.3.	“Affected
                                         Territory” means the geographic area of any country where there is an Outbreak
                                         or that is at risk of an Outbreak taking into account epidemiological data, travel and
                                         migration patterns and the lack of availability of other products or product candidates;

 

		1.1.4.	“Agreement”
                                         means this agreement including any Schedules attached hereto and any Work Package Statements
                                         and Additional Work Package Statements;

 

		1.1.5.	“Approved
                                         Regulatory Authority” means the EU European Medicines Agency, the US Food and
                                         Drug Administration, SwissMedic, Japanese PMDA, Australian Therapeutic Goods Agency,
                                         South Korean Ministry of Drug Safety, Health Canada, the United Kingdom Medicines and
                                         Healthcare Products Regulatory Agency (MHRA) or Singapore Health Sciences Authority and,
                                         in each case, any successor authority and any other regulatory authority agreed to by
                                         the Parties as being an Approved Regulatory Authority;

 

		1.1.6.	“Assessors”
                                         as defined in Clause 9.3

 

		1.1.7.	“Background
                                         Technology” means the Technology in the Field Controlled by Partner on the
                                         Effective Date, excluding, however, the Technology that Partner has licensed from Acuitas
                                         Therapeutics, Inc. (subject only to the limited license set forth below), and only to
                                         the extent such Technology is required for:

 

		(i)	undertaking
                                         any Work Packages or Additional Work Packages;

 

		(ii)	the
                                         protection or exploitation of Project Technology;

 

		(iii)	Developing
                                         the Platform;

 

		(iv)	Manufacturing
                                         Products; and

 

		(v)	the
                                         Technology Transfer of the Platform to Trusted Manufacturer(s).

 

    2

     

    

 

		1.1.8.	In
                                         accordance with and subject to the terms and conditions of this Agreement, included in
                                         the Background Technology will be a license from Acuitas Therapeutics, Inc. for the Project
                                         Vaccine, for a term of [*****] years after the Effective Date. Partner agrees to use
                                         its Reasonable Efforts to secure an extension of the [*****] years license on behalf
                                         of CEPI to cover use of this Background Technology for Project Vaccine in the Field for
                                         the term of this Agreement. The Background Technology is described in Schedule 3;

 

		1.1.9.	“Business
                                         Day” means a day on which banks are normally open for business and which is
                                         not a Saturday or Sunday, or a bank or public holiday in Norway, England and Wales or
                                         Germany;

 

		1.1.10.	“CEPI
                                         Group” means CEPI, including its offices in Norway, UK, India and the United
                                         States and its Affiliates;

 

		1.1.11.	“CEPI
                                         Production Timeframe” means CEPI’s timeframe for the Development and
                                         Manufacture of the Project Vaccine for use in the Field in the Affected Territory:

 

		(i)	release
                                         of Project Vaccine for use in clinical trials and commencement of clinical trial(s) in
                                         humans within [*****] weeks of the identification of the antigen with Outbreak Potential;

 

		(ii)	demonstration
                                         of the achievement of clinical benefit (i.e. an immune response likely to result in clinical
                                         benefit in humans) within [*****] weeks of the administration of the first dose of the
                                         Project Vaccine in humans in the clinical trial(s); and

 

		(iii)	Manufacture,
                                         fill, finish, release and distribution in the Affected Territory of [*****] doses of
                                         Project Vaccine within [*****] weeks of demonstration of clinical benefit;

 

		1.1.12.	“CEPI
                                         Policies” means the CEPI policies and procedures in effect as of the date of
                                         this Agreement as listed below and attached hereto as Schedule 10, together with
                                         any amendments thereto and any new policies and procedures acceded to by the Parties
                                         pursuant to Clause 4.2:

 

		(i)	Animals
                                         in Research Policy;

 

		(ii)	Clinical
                                         Trials Policy;

 

		(iii)	Equitable
                                         Access Policy;

 

		(iv)	Shared
                                         Risks/Shared Benefits Policy;

 

		(v)	Management
                                         of Technology;

 

		(vi)	Scientific
                                         Integrity;

 

		(vii)	Anti-Corruption
                                         Policy;

 

		(viii)	International
                                         Sanctions Policy;

 

    3

     

    

 

		(ix)	Policy
                                         for Managing Conflict of Interest;

 

		(x)	Procurement
                                         Policy and Procedures;

 

		(xi)	Transparency
                                         and Confidentiality Policy; and

 

		(xii)	Travel
                                         Policy.

 

For
the avoidance of doubt, the terms and conditions of this Agreement shall have precedents over the CEPI Policies.

 

		1.1.13.	“Commercial
                                         Benefits” means any financial and non-financial benefits, rewards and/or results
                                         generated from or arising from the exploitation of the Project Technology in the Field,
                                         resulting in any way from the CEPI funding and/or Partner Contribution or to which CEPI
                                         funding or the Partner Contribution have contributed in any way whatsoever, including
                                         any government-paid incentives such as Priority Review Vouchers (“PRV”) and
                                         other derivative or follow-on products (including antibodies and assays);

 

		1.1.14.	“Commercial
                                         Use” means the exploitation of the Project Technology in the Field;

 

		1.1.15.	“Condition(s)
                                         Precedent” as defined in Clause 12.1

 

		1.1.16.	“Confidential
                                         Information” means any and all non-public data, results, Know-How, software
                                         (including non-open source code), plans, details of research work, discoveries, inventions,
                                         intended publications, intended or pending patent applications, designs, technical information,
                                         business plans, budgets and strategies, business or financial information or other information
                                         in any medium and in any form, and any physical items, prototypes, compounds, samples,
                                         components, non-public Regulatory Filings, non-public submissions to Regulatory Authorities
                                         or other articles or Materials disclosed on or after the Effective Date of this Agreement
                                         by one Party to the other Party whether orally or in writing or in any other form;

 

		1.1.17.	“Contractor
                                         Result” means any tangible or intangible goods or services produced as a result
                                         of any work conducted by Sub-Contracting by a Partner pursuant to this Agreement and
                                         which is listed as a Contractor Result in the relevant Work Package Statement or is agreed
                                         to be a Contractor Result by the JMAG;

 

		1.1.18.	“Control”
                                         and “Controlled” shall mean with respect to the subject item, the
                                         possession (whether by ownership or license, other than pursuant to this Agreement) by
                                         a Party of the right to grant to the other Party access or a license as provided herein
                                         under such item or right without violating the terms of any agreement or other arrangement
                                         with any Third Party;

 

		1.1.19.	“Cost
                                         of Goods” means the formula for calculating the cost of goods set by Gates
                                         attached as Schedule 7 but excluding all CEPI funding for work included in the
                                         Work Packages or Additional Work Packages and other non-repayable public or philanthropic
                                         funding received by the Partner and used to Develop the Background Technology and the
                                         Project Technology and to Manufacture and market the Product for use in the Field in
                                         the Affected Territory;

 

    4

     

    

 

		1.1.20.	“Data”
                                         means any and all scientific, technical or test data including Know-How, research data,
                                         clinical pharmacology data, immunogenicity data, CMC data (including analytical and quality
                                         control data and stability data), pre-clinical data, clinical data, information concerning
                                         clinical trials, pharmacoeconomic data and data in publications, Regulatory Filings,
                                         submissions to Regulatory Authorities, Platform Confirmations, marketing approvals and
                                         Master Files related thereto;

 

		1.1.21.	“Defaulting
                                         Party” as defined in Clause 19.2

 

		1.1.22.	“Deliverables”
                                         means those tangible and/or intangible works or services which are to be delivered in
                                         accordance with the respective Work Package Statement or Additional Work Package Statement;

 

		1.1.23.	“Develop”
                                         or “Development” means those development activities that are required
                                         (i) to perform the Work Packages or Additional Work Packages with respect to the Project
                                         Vaccine; and (ii) to obtain Platform Confirmation from at least one Approved Regulatory
                                         Authority. Development of the Project Vaccine may include stability testing, toxicology,
                                         formulation and process development, CMC development, manufacturing process validation,
                                         statistical analysis, pre-clinical and clinical studies, as further defined in the applicable
                                         Work Package or Additional Work Package; and “Developing” shall be
                                         construed accordingly. For the avoidance of doubt, where this Agreement refers to “development”
                                         in the lower case, the same kinds of activities are contemplated; however, such activities
                                         will not occur pursuant to a Work Package between the Parties;

 

		1.1.24.	“Disclosure
                                         Letter” means the letter from the Partner to CEPI attached hereto as Schedule
                                         12, setting out disclosures known by the Partner against the Warranties;

 

		1.1.25.	“Documents”
                                         means reports, research notes, charts, graphs, comments, computations, analyses, recordings,
                                         photographs, paper, notebooks, books, files, ledgers, records, tapes, discs, diskettes,
                                         CD-ROMs, computer programs and documents thereof, computer information storage means,
                                         samples of material, other graphic or written data and any other media on which Know-How
                                         can be permanently stored;

 

		1.1.26.	“Effective
                                         Date” means the date of final execution of this Agreement;

 

		1.1.27.	“Field”
                                         means the diagnosis, prevention and treatment of infections caused by:

 

    5

     

    

 

		(i)	the
                                         pathogens listed in the WHO R&D blueprint priority (December 2015 or January 2017)
                                         as updated from time to time (including: Arenaviral hemorrhagic fevers (including Lassa
                                         Fever), Crimean Congo Haemorrhagic Fever (CCHF), Filoviral diseases (including Ebola
                                         and Marburg), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (or other highly
                                         pathogenic coronaviral diseases, such as SARS), Nipah and related henipaviral diseases,
                                         Rift Valley Fever (RVF), Severe Fever with Thrombocytopenia Syndrome (SFTS) and Zika
                                         unless, at the time of CEPI’s request to work with Partner, Partner is already
                                         committed to working with Gates based on a proposal according to the Global Access Commitments
                                         Agreement dated February 13, 2015;

 

		(ii)	Chikungunya;

 

		(iii)	Lassa
                                         Fever; and

 

	

     	(iv)

     	novel or previously unrecognized pathogens likely to
    result in an Outbreak or risk of an Outbreak unless, at the time of CEPI’s request to work with Partner, Partner is
    already committed to working with Gates based on a proposal according to the Global Access Commitments Agreement dated February
    13, 2015 or unless products to treat such infections are already commercialized, commercialization has failed, or Partner
    has a commercial interest in such products. Such commercial interest of Partner is assumed for the following pathogens: [*****].
    If CEPI is interested to develop a product with respect to such novel or previously unrecognized pathogen under this Agreement,
    it shall notify Partner hereof and Partner shall respond within [*****] business days as of the notification whether the product
    is within or outside the Field, and with respect to any such pathogen other than the ones listed above for which the commercial
    interest is assumed, Partner shall provide information on its commercial interest. With respect to pathogens which fall under
    this (iv), for which the Partner has previously declared commercial interest, and for which the commercial interest is not
    assumed, CEPI may after six (6) months as from Partner’s providing the aforementioned information reasonably request
    from Partner a confirmation including appropriate information, that Partner’s commercial interest continues and consequently
    such pathogen remains to be outside the Field.

 

		1.1.28.	“Financial
                                         Documents” means:

 

		(i)	the
                                         Financial Summary and Reporting Form; and

 

		(ii)	the
                                         most recent audited financial statement of the Partner, auditor’s report for such
                                         financial statement and management letter to the auditors for such financial statement,
                                         and

 

		(iii)	where
                                         requested by CEPI pursuant to Clause 3.13, the most recent audited Project statements;

 

		1.1.29.	“Financial
                                         Summary and Reporting Form” means a report by the Partner to CEPI in the prescribed
                                         form (a template which is attached as Schedule 8) providing up-to-date details
                                         of actual and forecast costs for each current Work Package or Additional Work Package;

 

		1.1.30.	“Gates”
                                         means the Bill & Melinda Gates Foundation of P.O. Box 23350, Seattle WA 98102, USA;

 

		1.1.31.	“Improvements”
                                         means any improvement, modification, enhancement and update and includes all Technology
                                         related thereto;

 

		1.1.32.	“Initial
                                         Project Term” means [*****] years as from the Effective Date;

 

    6

     

    

 

		1.1.33.	“IPDP”
                                         means the Integrated Product Development Plan setting out the studies and other activities
                                         to be performed in a Work Package or Additional Work Package, using the CEPI funding
                                         attached as Schedule 6;

 

		1.1.34.	“JMAG”
                                         has the meaning set forth in Clause 5.3;

 

		1.1.35.	“Know-How”
                                         means any technical and other information which is not in the public domain, including
                                         information comprising or relating to concepts, discoveries, data, designs, formulae,
                                         ideas, inventions, methods, models, assays, research plans, procedures, designs for experiments
                                         and tests and results of experimentation and testing (including results of research or
                                         development), processes (including manufacturing processes, specifications, and techniques),
                                         laboratory records, chemical, pharmacological, toxicological, clinical, analytical and
                                         quality control data, trial data, case report forms, data analyses, reports, manufacturing
                                         data or summaries and information contained in submissions to and information from ethical
                                         committees and Regulatory Authorities (including the Master File) and computer programs
                                         or algorithms including those relating to manufacturing and source code for manufacturing
                                         processes. Know-How includes Documents containing Know-How, including any rights such
                                         as trade secrets, copyright, database or design rights protecting such Know-How. The
                                         fact that an item is known to the public shall not be taken to preclude the possibility
                                         that a compilation including the item, or a development relating to the item, is not
                                         known to the public;

 

		1.1.36.	“Manufacturing”
                                         or “Manufacture” means subject to GMP, production on the Platform
                                         of Project Vaccine and Products or constituents thereof, including active ingredients,
                                         excipients, adjuvants, preservatives or other additives;

 

		1.1.37.	“Master
                                         File” means all drug master files relating to Product that may be filed with
                                         any Regulatory Authority;

 

		1.1.38.	“Material”
                                         means any chemical or biological substance including any: organic or inorganic element;
                                         nucleotide or nucleotide sequence including DNA and RNA sequences; gene; vector or construct
                                         including plasmids, phages or viruses; host organism including bacteria, fungi, algae,
                                         protozoan; hybridomas; eukaryotic or prokaryotic cell line or expression system or any
                                         development strain or product of that cell line or expression system; protein including
                                         any peptide or amino acid sequence, enzyme, antibody or protein conferring targeting
                                         properties and any fragment of a protein or a peptide enzyme or antibody; drug or pro-drug
                                         including bulk drug substance, filled product and any manufacturing intermediates; assay
                                         or reagent; any other genetic or biological material or micro-organism; transgenic animals,
                                         clinical samples and up to date pathogen samples;

 

		1.1.39.	“Milestone”
                                         has the meaning as set forth in Clause 3.6;

 

		1.1.40.	“Milestone
                                         Criteria” means the criteria described in the relevant Work Package Statement
                                         which the Parties target to achieve by agreed dates (the “Milestone Dates”).
                                         The Milestone Criteria and Milestone Date(s) for each Work Package/Additional Work Package
                                         are set out in the relevant Work Package Statement or Additional Work Package Statement;

 

		1.1.41.	“Outbreak”
                                         means:

 

    7

     

    

 

		(i)	the
                                         occurrence in a community or region of cases of an illness with a frequency in excess
                                         of normal expectancy;

 

		(ii)	a
                                         public health emergency of international concern declared by WHO; and/or

 

		(iii)	a
                                         public health emergency on a national or regional scale declared by the relevant national
                                         or regional government;

 

		1.1.42.	“Parties”
                                         means the parties to this Agreement and “Party” shall be interpreted
                                         accordingly;

 

		1.1.43.	“Partner
                                         Contribution” means the financial and in-kind contributions to be made by the
                                         Partner to any Work Package/Additional Work Package as set out in Schedule 2 and
                                         individual Work Package Statements/Additional Work Package Statements, but excluding
                                         any of the Partner’s sunk costs as of the Effective Date in the Platform and/or
                                         the Project Vaccines to be developed under the Project as of the Effective Date;

 

		1.1.44.	“Partner
                                         Financial Records” means accounting and other financial records relating to
                                         the CEPI funding, Partner Contribution and the activities funded by the foregoing, income
                                         and expenditure associated with the Project, the Platform, and the systems used by the
                                         Partner to administer the Project financially and otherwise;

 

		1.1.45.	“Partner’s
                                         Right of First Refusal” shall have the meaning given to it in Clause 8.3.3;

 

		1.1.46.	“Payment
                                         Schedule” means the schedule setting out the proposed dates for payments of
                                         CEPI funding and/or payments or contributions comprising the Partner Contribution set
                                         out in the relevant Work Package Statement/Additional Work Package Statement;

 

		1.1.47.	“Platform”
                                         means the automation solution for Partner’s processes of RNA manufacturing developed
                                         by Partner and Tesla Grohmann Automation Solution GmbH (“TGA”) under the
                                         Development and Intellectual Property Agreement dated December 22, 2017, including the
                                         Know-How licensed from TGA thereunder;

 

		1.1.48.	“Platform
                                         Confirmation” means the approval of the Platform by Regulatory Authorities,
                                         taking into account that currently Regulatory Authorities do not in general have the
                                         legal power to grant marketing approval for vaccine production platforms, obtaining confirmation
                                         from Regulatory Authorities that applications for approval of clinical trials may rely
                                         on existing Data prepared in conjunction with the application for prior vaccines developed
                                         on the Platform;

 

		1.1.49.	“Product”
                                         means any form or dosage of pharmaceutical composition or preparation for use in humans
                                         which is intended to prevent, diagnose or treat diseases within the Field and in an Affected
                                         Territory, and which incorporates, comprises or relies on the Background Technology and/or
                                         the Project Technology, and/or is Manufactured on the Platform. Product may be a Project
                                         Vaccine. For the avoidance of doubt, a Product may be developed or Manufactured outside
                                         of the Affected Territory, but exclusively for marketing within the Affected Territory;

 

		1.1.50.	“Project
                                         Lead” means [*****] of the Partner;

 

    8

     

    

 

		1.1.51.	“Project”
                                         means the activities set out in the Work Package Statements/Additional Work Package Statements;

 

		1.1.52.	“Project
                                         Standards” shall have the meaning given to it in Clause 4;

 

		1.1.53.	“Project
                                         Technology” means Technology that is created, devised or arises out of the
                                         undertaking and performance of any Work Package/Additional Work Package, the activities
                                         set out in the IPDP and any other activities undertaken and performed pursuant to this
                                         Agreement;

 

		1.1.54.	“Project
                                         Term” shall have the meaning set forth in Clause 19.1;

 

		1.1.55.	“Project
                                         Vaccine” means vaccines targeting Lassa, to be Developed and Manufactured,
                                         pursuant to this Agreement;

 

		1.1.56.	“Public
                                         Health License” has the meaning given to it at Clause 11.1;

 

		1.1.57.	“Quarterly
                                         Report” means a written report to CEPI in the form of the template in Schedule
                                         9 outlining Work Package/Additional Work Package progress, key risks and risk mitigation
                                         strategies and up to date financial details relating to the Project;

 

		1.1.58.	“Reasonable
                                         Efforts” means:

 

		(i)	with
                                         respect to the Partner, in good faith making no less commercially reasonable effort and
                                         committing no less resources than those commonly used by the Partner or, if greater,
                                         a company of similar size and with similar resources to the Partner and its Affiliates
                                         in the vaccine industry when applied to platforms, compounds, vaccines and products at
                                         a similar stage of development, life cycle and healthcare potential to the Platform and
                                         Product being developed, taking into account (a) all relevant factors including issues
                                         of safety and efficacy, product profile, difficulty in Developing or Manufacturing, sourcing
                                         raw materials necessary therefor, regulatory approvals, the patent or other proprietary
                                         position of the Platform or Project Vaccine and the regulatory requirements involved;
                                         and (b) the Parties’ joint aim of developing the Platform and Project Vaccine in
                                         a diligent and timely manner as indicated by the Milestones and Milestone Dates;

 

		(ii)	with
                                         respect to the CEPI Group, the use of reasonable efforts and resources, in good faith,
                                         in the exercise of prudent legal, medical, scientific judgement (as applicable) considering
                                         CEPI’s mission and the healthcare potential of the applicable Platform and Product;

 

		1.1.59.	“Regulatory
                                         Authority” means any governmental authority whose review or approval is necessary
                                         or useful for the development and/or marketing activities of the Product in a given country
                                         in the Affected Territory including the Approved Regulatory Authorities;

 

		1.1.60.	“Regulatory
                                         Filing” means all approvals, licenses, registrations, variations applications,
                                         submissions and authorizations made to or received from a Regulatory Authority necessary
                                         for the development and/or marketing activities of Product including INDs, and the Master
                                         File relating to the Product;

 

    9

     

    

 

		1.1.61.	“RNA
                                         Optimizer Toolkit” shall mean the methodology used and processes applied at
                                         Partner at the date of CEPI’s request according to Clause 8.3.3 to provide optimized
                                         nucleotide sequences;

 

		1.1.62.	“Safety
                                         Issues” shall have the meaning given to it in Clause 7.11.6;

 

		1.1.63.	“Stage
                                         Gate” means a point of control where the Parties determine as to whether a
                                         Work Package/Additional Work Package has been completed or a Milestone Criterion has
                                         been achieved;

 

		1.1.64.	“Stage
                                         Gate Criteria” means the criteria described in the relevant agreed Work Package
                                         Statement/Additional Work Package Statement that CEPI requires to be satisfied, including
                                         the dates specified in the Work Package Statement/Additional Work Package Statement for
                                         satisfaction of the Stage Gate Criteria (the “Stage Gate Dates”) for
                                         CEPI to advance the Project;

 

		1.1.65.	“Sub-Contract(s)”
                                         contracts concluded between Partner and Sub-Contractor;

 

		1.1.66.	“Sub-Contractor”,
                                         shall have the meaning set forth in Clause 10.1.1;

 

		1.1.67.	“Team
                                         Charter” means the Team Charter attached as Schedule 11, which includes,
                                         for example, the composition of the JMAG and the procedures on how the JMAG renders decisions;

 

		1.1.68.	“Technology”
                                         means any Know-How together with all intellectual property rights and similar or equivalent
                                         rights anywhere in the world which currently exist or are recognized in the future (whether
                                         or not registered) covering such Know-How; and applications, extension and renewals in
                                         respect of the foregoing including patent applications, patents resulting from any such
                                         applications, utility certificates, improvement patents and models, certificates of addition
                                         and all foreign counterparts in all countries, including any divisional applications
                                         and divisional patents, refiling, renewals, continuations, continuations-in-part, patents
                                         of addition, extensions (including patent term extensions), reissues, substitutions,
                                         confirmations, registrations, re-validations, pipeline and administrative protections
                                         and additions, supplementary protection certificates and equivalent protection, designs,
                                         trademarks and trade names, copyright and related rights, and database rights;

 

		1.1.69.	“Technology
                                         Transfer Materials” means the materials required to be made available to a
                                         Trusted Manufacturer to enable such Trusted Manufacture to (i) adapt, develop and use
                                         the Platform for the Manufacture of Products for use in the Field and in the Affected
                                         Territories (ii) develop, formulate, recreate and show equivalence (where relevant) to
                                         Products developed by Partner under an Additional Work Package. For the avoidance of
                                         doubt, Technology Transfer Materials do not include RNA Optimizer Toolkit technology.

 

		1.1.70.	“Terminating
                                         Party” as defined in Clause 19.2;

 

		1.1.71.	“Termination
                                         Date” shall have the meaning set forth in Clause 20.1;

 

		1.1.72.	“Third
                                         Party” means a legal entity other than a Party and a Party’s Affiliates;

 

    10

     

    

 

		1.1.73.	“Transfer
                                         Agent” as defined in Clause 9.3.

 

		1.1.74.	“Trusted
                                         Manufacturer” means a Third Party nominated by the Partner and appointed by
                                         CEPI, or nominated by CEPI and appointed by the Partner if so agreed in Additional Work
                                         Package Statements;

 

		1.1.75.	“Underspend”
                                         means any CEPI funding paid to the Partner for a given Work Package/Additional Work Package
                                         that is unspent (as reflected by the Partner’s actual expenditure in the Partner’s
                                         Financial Summary and Reporting Form) following completion of the work specified in a
                                         Work Package Statement/Additional Work Package Statement or at the date of termination
                                         of expiration of this Agreement;

 

		1.1.76.	“Wellcome”
                                         means The Wellcome Trust Limited as trustee of the Wellcome Trust of 215 Euston Road,
                                         London NW1 2BE;

 

		1.1.77.	“Work
                                         Package” means the activities to be done under the Project agreed between the
                                         Parties as of the Effective Date, including Work Packages 3 and 5 which need to be refined
                                         and agreed upon at a later stage, and any future activities agreed by the Parties to
                                         be described in an “Additional Work Package”;

 

		1.1.78.	“Work
                                         Package Budget” means the maximum amount of funding to be provided by CEPI
                                         to the Partner for the relevant Work Package as set out in the Work Package Statement;
                                         and

 

		1.1.79.	“Work
                                         Package Statement” means the statement of activities, timeline, Partner Contribution,
                                         Milestones, Milestone Dates, Work Package Budget and Payment Schedule for a particular
                                         Work Package agreed between the Parties. The template for Work Package Statements is
                                         attached as Schedule 1 and the Work Package Statements for Work Packages 1, 2
                                         and 4 are attached as Schedule 5 (with Work Packages 3 and 5 to be finalized and
                                         signed later).

 

		1.2	Any
                                         phrase introduced by the terms “including”, “include”, “in
                                         particular” or any similar expression shall be construed as illustrative and shall
                                         not limit the sense of the words preceding those terms.

 

		1.3	Any
                                         provision in this Agreement referring to “Project Vaccine” will apply respectively
                                         to any Product which the Parties will agree to develop under an Additional Work Package.

 

		1.4	Where
                                         reference is made in this Agreement to any Party’s prior written consent being
                                         required in respect of any matter, the respective other Party shall give not less than
                                         [*****] written notice to such Party of the matter for which such consent is required
                                         or a different period of time mutually agreed in writing by the Parties.

 

    11

     

    

 

		2.	PROJECT
                                         OBJECTIVES

 

		2.1	CEPI
                                         is entering into this Agreement to further CEPI’s mission by developing a vaccine
                                         platform technology that can be available for use in outbreaks of infectious diseases
                                         with epidemic potential to enable rapid vaccine development, manufacture, scale up and
                                         clinical benefit at a cost of goods in line with the methodology to determine pricing
                                         obligations set out in the CEPI Equitable Access Policy and the Cost of Goods to address
                                         global health concerns.

 

		2.2	Partner
                                         is supporting CEPI to fulfill its mission, while it is interested to advance the Platform
                                         for the manufacture of mRNA based products.

 

		3.	PROJECT
                                         FUNDING

 

		3.1	Project
                                         Funding. CEPI agrees to contribute funding for the Project of up to a maximum amount
                                         of US $ 34,022,694 United States Dollars subject to the terms and conditions of this
                                         Agreement. The budget for the Project (excluding the Partner Contribution) as of the
                                         Effective Date is set out in Schedule 4.

 

		3.2	Payment
                                         Administration. CEPI shall make all payments to the Partner in United States Dollars
                                         (USD ($)) unless otherwise agreed between the Parties by electronic wire transfer of
                                         immediately available funds directly to the Partner’s bank account designated below:

 

Account
Name:[*****]

 

Account
No.:[*****]

 

Bank:[*****]

 

Sort
code:[*****]

 

Swift
code:[*****]

 

Branch:[*****]

 

Account
Currency: USD

 

Partner
shall ensure that the bank account designated above is a separate bank account with a bank with credit rating A, is in the name
of the Partner, is described as a CEPI funding account and that the bank account does not go into debit during the Project Term.

 

		3.3	Work
                                         Packages. The Project to be funded under this Agreement comprises a number of Work
                                         Packages. The Work Package Statements and Work Package Budgets agreed between the Parties
                                         for the Work Packages are set out in Schedule 5. The undertakings in those documents
                                         setting forth the undertakings hereunder (like to Develop, Manufacture and mmarket) shall
                                         prevail the undertakings set forth in general terms hereunder. This shall also apply
                                         to parameters set forth in those Work Packages that deal with or modify the CEPI Production
                                         Timeframe. As of the Effective Date, the Parties have agreed upon three (3) Work Packages
                                         which form an integral part of this Agreement, subject to the terms and conditions of
                                         this Agreement. [*****] further Work Packages [*****] will be finalized and signed between
                                         the Parties after the Effective Date subject to a successful Stage Gate Review.

 

		3.4	First
                                         Payment. CEPI’s practice is to make biannual funding payments in advance for
                                         the work planned to take place in the next [*****] period. CEPI will pay the [*****]
                                         tranche of CEPI funding for the Work Packages to the Partner within [*****] of the latter
                                         of receipt by CEPI of a payment request for the relevant amount or execution of this
                                         Agreement by the last of the Parties hereto.

 

    12

     

    

 

		3.5	Subsequent
                                         payments. Partner must request payment of subsequent tranches of CEPI funding by
                                         providing CEPI with:

 

		3.5.1.	a
                                         payment request for the relevant amount on or prior to the date set out in the relevant
                                         payment schedule;

 

		3.5.2.	Quarterly
                                         Reports for two calendar quarters immediately prior to the payment request; and

 

		3.5.3.	up
                                         to date, true, complete and accurate Financial Documents.

 

CEPI
will pay subsequent tranches of CEPI funding for the relevant Work Package(s) within [*****] of receipt of the documents referred
to above. CEPI may reschedule or adjust future payments of CEPI funding to address any Underspend that is not returned to CEPI
and is carried over by notice in writing to the Partner.

 

		3.6	Milestones.
                                         Each Work Package Statement sets out one or more milestones (each a “Milestone”)
                                         for that Work Package together with Milestone Criteria and the Milestone Dates for the
                                         Milestone(s). When the Partner considers that a Milestone has been completed, the Partner
                                         shall promptly notify CEPI and as soon as reasonably practicable provide the JMAG with
                                         a report setting out evidence of the achievement of the Milestone Criteria by the relevant
                                         Milestone Date.

 

		3.7	Stage
                                         Gates. On the completion of each Work Package, CEPI will conduct a review of Project
                                         progress (“Stage Gate Review”) by convening a CEPI-selected “Stage
                                         Gate Committee.” The Partner agrees to participate in the Stage Gate Review and
                                         to provide reasonably requested information and hold face-to-face meetings with the Stage
                                         Gate Committee and CEPI in a timely fashion to avoid disruption and delay between Work
                                         Packages. When the Partner considers that a Work Package has been completed, the Partner
                                         shall promptly notify CEPI and, as soon as reasonably practicable, provide CEPI with
                                         a report setting out evidence of the achievement of the Stage Gate Criteria by the relevant
                                         Stage Gate Date or, where any Stage Gate Criteria or Stage Gate Date have not been achieved,
                                         a detailed explanation with supporting evidence as to why this was the case. If the Stage
                                         Gate Committee has concerns in relation to the documents referred to above, CEPI shall
                                         provide reasonable details of the concerns to Partner and may request additional information.
                                         CEPI shall, as soon as reasonably practicable, notify the Partner whether CEPI is willing
                                         in principle to fund Work Package 4.3, Work Packages 3 and 5 or the next planned Additional
                                         Work Package(s) or declines to fund the next planned Additional Work Package(s). Where
                                         CEPI is willing to fund the next planned Additional Work Package(s), the Partner promptly
                                         shall provide CEPI with a draft Additional Work Package Statement(s) and the Parties
                                         shall agree and sign the Additional Work Package Statement(s) in good faith within [*****]
                                         to ensure smooth transition for activities to be pursued in any such Additional Work
                                         Packages.

 

		3.8	No
                                         obligation to fund. CEPI is not obliged to make any payment of CEPI funding to the
                                         Partner under this Agreement where:

 

		3.8.1.	CEPI
                                         and/or the Partner have not agreed and/or signed the applicable Work Package Statement;
                                         and/or

 

    13

     

    

 

 

		3.8.2.	the
                                         Partner has breached a material obligation set out in this Agreement that is incapable
                                         of remedy or has not been remedied within the applicable cure period;

 

		3.9	Use
                                         of CEPI funding. Partner agrees to use CEPI funding and Partner Contribution in accordance
                                         with the Work Package Budgets for the purposes described in the relevant Work Package
                                         Statements unless otherwise agreed in writing by CEPI in advance.

 

		3.10	Amendment
                                         of Work Package Statements. During the course of a given Work Package, circumstances
                                         may arise, which necessitate amendment of a Work Package Statement. The Partner shall
                                         notify CEPI promptly of the need for amendment of a Work Package Statement and provide
                                         suggested amendments and written justification for same to CEPI. The Parties agree to
                                         use reasonable endeavors to negotiate and agree in good faith necessary amendments within
                                         [*****] to ensure the continuity of the Project and the Work Package.

 

		3.11	Third
                                         Party funding or support for the Project. The Partner may seek other funding or support
                                         (whether in kind or otherwise) for the Project or any Work Package, whether commercial
                                         or non-commercial but undertakes not to accept such funding without CEPI’s prior
                                         written consent.

 

		3.12	Expenditure
                                         of CEPI funding. The Partner shall ensure that the control of expenditure of the
                                         CEPI funding and the Partner Contribution are governed by the normal standards, procedures
                                         and formal audit arrangements that exist in the Partner. CEPI shall have the right to
                                         ask for confirmation from the Partner’s external auditors that the external auditors
                                         have signed their opinion on the Partner’s annual accounts of the Partner without
                                         qualification and the management letter from the auditors raises no matters that did
                                         or could significantly affect the administration of grants awarded by CEPI. If the auditors
                                         have raised any such matters in their management letter, CEPI may require the Partner
                                         to provide it with relevant extracts from the letter and/or other information.

 

		3.13	Project
                                         Audit. On CEPI’s reasonable request, and no more often than once every [*****]
                                         the Partner shall procure the Partner’s external auditors to conduct a Project
                                         audit and to provide CEPI with audited Project statements (in accordance with ISA800)
                                         at CEPI’s cost and expense.

 

		3.14	Terrorism.
                                         Partner will use all Reasonable Efforts to ensure that no CEPI funding will be used to
                                         fund individuals or entities associated with terrorism.

 

		3.15	Partner
                                         Financial Records. The Partner shall maintain and retain the Partner Financial Records
                                         for [*****] from the end of the financial year the records relate to.

 

		3.16	Audit
                                         by CEPI. The Partner shall provide access to the Partner Financial Records to auditors
                                         and other personnel from or appointed by CEPI: (i) annually at a mutually agreeable time
                                         and location, (ii) on request from CEPI, where CEPI has reasonable grounds indicating
                                         that the Partner is in breach of a material obligation under this Agreement, has misapplied
                                         CEPI funding or misstated the Partner Contribution; and (iii) on request from CEPI where
                                         CEPI is subject to a financial review or audit required by law or by one or more of CEPI’s
                                         funders. Such access shall include the right to reasonably inspect during regular business
                                         hours at times coordinated with the Partner any equipment or facilities acquired or funded
                                         under the CEPI funding or Partner Contribution. CEPI shall bear the cost of the audit
                                         unless the Partner is shown to have breached a material obligation of this Agreement,
                                         have misapplied CEPI funding or overstated the Partner Contribution. In these circumstances
                                         the Partner shall bear the reasonable costs of CEPI’s auditors.

 

    14

     

    

 

		3.17	Specific
                                         Project cost code. The Partner shall maintain a separate accounting cost code specific
                                         to the Project, and all costs and income properly relating to the Project (including
                                         the Partner Contribution) shall be accounted for through that cost code. The Partner
                                         shall ensure that appropriate records are kept supporting the entries made on the cost
                                         code.

 

The
provisions in this Clause 3 shall apply mutatis mutandis to Additional Work Packages and Additional Work Package Statements.

 

		4.	PROJECT,
                                         STANDARDS AND RECORDS MANAGEMENT

 

		4.1	Project
                                         Standards. In performing its obligations under this Agreement, the Partner shall
                                         comply with all applicable laws and requirements (including those of Regulatory Authorities),
                                         the terms and conditions of this Agreement and the CEPI Policies (the “Project
                                         Standards”). The Partner is responsible for the management, monitoring and
                                         control of all work undertaken by or on behalf of the Partner under any Work Package
                                         and compliance with the Project Standards.

 

		4.2	New
                                         CEPI Policies and amendments to CEPI Policies. CEPI shall give the Partner at least
                                         [*****] advance notice of the introduction of any new CEPI policy or amendment, update
                                         or withdrawal of a CEPI Policy together with a copy of the new or amended CEPI Policy.
                                         Where the new CEPI policy or update, amendment or withdrawal will, or is likely to have,
                                         a material impact on this Agreement, the Parties shall consult and agree in good faith
                                         how to proceed and CEPI shall consider in good faith any reasonable suggestions, comments
                                         or concerns raised by the Partner. Subject to agreement by the Partner, any updated or
                                         amended CEPI Policy shall replace the equivalent existing CEPI Policy and Schedule
                                         10 shall be updated accordingly.

 

		4.3	Animals
                                         in Research. Where any Work Package includes work involving animals, the Partner
                                         must ensure that such work complies with both the Wellcome policy on the use of animals
                                         in research and the principles set out in the document “Responsibility in the use
                                         of animals in bioscience research: Expectations of the major research council and charitable
                                         funding bodies” (http://www.wellcome.ac.uk/About-us/Policy/Policy-and-position-statements/WTD040129.htm).
                                         If procedures regulated under the UK Animals (Scientific Procedures) Act 1986 are to
                                         be used in any Work Package, the research must comply with such Act (regardless of where
                                         the work is carried out), be approved by the local ethical review process and be conducted
                                         with due consideration for the principles of the 3Rs (replacement, reduction and refinement
                                         of the use of animals in research).

 

		4.4	Research
                                         involving human participants. Where any Work Package includes work involving human
                                         subjects, the Partner must ensure that such work complies with requirements of Clause
                                         9 and:

 

		(i)	The Wellcome Trust’s
                                         Policy on Clinical Trials (https://wellcome.ac.uk/funding/guidance/wellcome-trust-policy-position-clinical-trials),

 

    15

     

    

 

		(ii)	the Wellcome Trust’s
                                         Policy on Research involving human participants (https://wellcome.ac.uk/funding/guidance/wellcome-trust-policy-position-research-involving-human-participants);

 

		(iii)	the Wellcome Trust’s
                                         Policy on the use of personal information in research (https://wellcome.ac.uk/funding/guidance/policy-use-personal-information-research),
                                         and

 

		(iv)	the Wellcome Trust’s
                                         guidance notes on research involving people in low- and middle- income countries (https://wellcome.ac.uk/funding/guidance/guidance-notes-research-involving-people-low-and-middle-income-countries).

 

		4.5	Project
                                         Records. The Partner shall ensure that all staff and Sub-Contractors working on the
                                         Project keep full, detailed and accurate records of all of their activities and results
                                         obtained in connection with each Work Package of the Project; including scientific records
                                         of all research, development and other work carried out in respect of each Work Package
                                         of the Project and the results of such research, development and other work is performed
                                         in accordance with GLP, GCP and GMP as applicable and in a way which is appropriate for
                                         patenting and regulatory purposes.

 

		4.6	Access
                                         to records. Upon CEPI’s request, the Partner shall make available (and shall
                                         procure that its Sub-Contractors make available) to CEPI all records generated in connection
                                         with any Work Package of the Project (except for any records which at the time of the
                                         request should remain blinded to CEPI in the interests of the integrity of a clinical
                                         trial).

 

		4.7	Accuracy
                                         of data. The Partner shall use Reasonable Effort to ensure that the Data it maintains
                                         and reports to CEPI and the JMAG, are complete, reliable, accurate and not misleading.

 

The provisions
in this Clause 4 shall apply mutatis mutandis to Additional Work Packages and Additional Work Package Statements.

 

		5.	PROJECT
                                         MANAGEMENT AND OVERSIGHT

 

		5.1	Project
                                         Lead. The Partner shall ensure that the Project is managed and operated in accordance
                                         with the Team Charter set out in Schedule 11 and shall ensure that the Project
                                         Lead has sufficient Project management support to ensure efficient co-ordination of each
                                         Work Package on a day-to-day basis.

 

		5.2	Project
                                         Lead replacement. If the Project Lead ceases to be involved with the Project, ceases
                                         to be employed by or provide services to the Partner, ceases to carry out research at
                                         premises controlled by the Partner, is prevented from working on the Project through
                                         illness or injury for a period of over [*****] or dies, the Partner shall promptly notify
                                         CEPI and the Parties will agree on a suitable replacement Project Lead as soon as possible,
                                         such agreement not be unreasonably withheld, delayed or conditioned by CEPI.

 

		5.3	Joint
                                         Monitoring and Advisory Group. The Parties shall establish and operate a joint monitoring
                                         and advisory group (the “JMAG”) in accordance with the Team Charter.

 

    16

     

    

 

		5.4	Project
                                         oversight. CEPI may appoint a site visit group made up of a small team of independent
                                         experts together with some CEPI observers (including representatives of CEPI’s
                                         funders) to consult with the Partner’s staff working on the Project, to evaluate
                                         progress, performance and key issues and to report back to CEPI and the JMAG on its findings.
                                         The Stage Gate Committee (described above) also will be involved in Project oversight.
                                         The site visit group shall be bound by confidentiality obligations towards the Partner,
                                         no less strict than CEPI’s confidentiality obligations towards the Partner. CEPI
                                         shall notify Partner in advance of any independent expert who is an employee or contractor
                                         of Third Parties who develop, manufacture and/or otherwise use competitive mRNA technologies.
                                         Partner shall have a right to object to the appointment of such independent expert if
                                         it has reasonable grounds to believe that such independent expert may get access to Confidential
                                         Information. Partner agrees that the site visit group shall have reasonable access during
                                         normal working hours and at mutually agreed times to visit the premises where any Work
                                         Package activities are being conducted. The site visit group will report back to CEPI
                                         on the progress, management and conduct of the then-current Work Package and Project.
                                         CEPI will share information from the site visit group with the JMAG.

 

The
provisions in this Clause 5 shall apply mutatis mutandis to Additional Work Packages and Additional Work Package Statements.

 

		6.	IPDP

 

		6.1	Current IPDP. Schedule
                                         6 sets out the IPDP agreed between the Parties as of the Effective Date.

 

		6.2	Amendment
                                         of IPDP. The Parties recognize that the IPDP will need to be amended and refined
                                         over time as more information becomes available. The Partner is responsible for keeping
                                         the IPDP up to date and amending, expanding, altering and refining the IPDP. Where CEPI
                                         funding or the Partner Contribution is used to fund specific Development activities as
                                         part of the Project, any amendment, expansion, alteration or refinement to the IPDP affecting
                                         the Work Packages must be agreed in writing by the JMAG and any corresponding amendments
                                         to any Work Package Statement must also be agreed in writing by the Parties.

 

The
provisions in this Clause 6 shall apply mutatis mutandis to Additional Work Packages and Additional Work Package Statements.

 

		7.	PARTNER
                                         OBLIGATIONS

 

		7.1	Project.
                                         The Partner agrees to use Reasonable Efforts during the Project to:

 

		7.1.1.	perform
                                         and complete the activities detailed in the Work Package Statements for each Work Package
                                         funded by the CEPI funding and/or the Partner Contribution in accordance with the agreed
                                         timeframe for such Work Package and within the agreed budget for such Work Package;

 

		7.1.2.	achieve
                                         the Milestone Criteria and Stage Gate Criteria for each Work Package by the applicable
                                         Milestone Dates and Stage Gate Dates; provided that if the performance of criteria under
                                         a Work Package Statement is delayed or otherwise not achieved, but likely to be achieved
                                         in due course, the Parties may agree for the Milestone Criteria and/or Stage Gate Criteria
                                         to be met, or the Milestone and/or Stage Gate Dates to be extended; and

 

    17

     

    

 

		7.1.3.	complete the Project
                                         by [*****]

 

		7.2	Regulatory.
                                         Subject to specific Work Packages, the Partner agrees to use Reasonable Efforts develop
                                         the regulatory strategy for the Platform for use in the Field and the Project Vaccine
                                         for use in the Field, in both cases in accordance with the relevant Work Package Statement
                                         for review and approval by JMAG. Such strategy shall include the strategy with respect
                                         to any data, market or other regulatory exclusivity periods that may be applicable in
                                         the Affected Territory or a territory which may be served by an Approved Regulatory Authority.

 

		7.3	IND
                                         or CTA. Subject to specific Work Packages, the Partner agrees to use Reasonable Efforts
                                         to file for, obtain and maintain an IND or a CTA for Project Vaccine Developed by Partner
                                         for use in the Field in both a territory served by an Approved Regulatory Agency and
                                         the Affected Territory.

 

		7.4	Master
                                         Files for the Platform, and for the commercial use of Project Vaccine. At the request
                                         and cost of CEPI pursuant to a specific request from a Regulatory Agency, the Partner
                                         agrees to provide copies of Master Files and existing Data for Products to Regulatory
                                         Authorities that request such information to support Regulatory Filings and submissions
                                         for the Platform and/or for Project Vaccines for use in the Field.

 

		7.5	Meetings
                                         with Regulatory Authorities. The Partner shall invite a CEPI nominee to observe relevant
                                         interactions between the Partner and Regulatory Authorities relating to the Platform
                                         and Project Vaccines for use in the Field. At CEPI’s reasonable request, the Partner
                                         will request a meeting with Regulatory Authorities to deal with any significant unresolved
                                         issues. The Parties acknowledge and agree that CEPI is bound by confidentiality obligations
                                         to the Partner pursuant to Clause 17 of this Agreement and that confidentiality concerns
                                         will not prevent the Partner and the Regulatory Authorities from having open and frank
                                         discussions in CEPI’s presence.

 

		7.6	Trusted
                                         Manufacturers. Subject to the undertakings to be defined in the Additional Work Packages
                                         and - upon Partner’s request, subject to a separate confidentiality agreement to
                                         be concluded between the Partner and the Trusted Manufacturer - the Partner will support
                                         CEPI in appointing one or more Trusted Manufacturers that are technically and operationally
                                         capable of and willing to rapidly Manufacture Product for use in the Field in the Affected
                                         Territory on an ongoing basis both during and after completion of the Project, in accordance
                                         with CEPI’s requirements, as set forth herein.

 

7.6.1.       Subject
to the undertakings in the Additional Work Packages the Partner shall:

 

		(i)	grant
                                         appointed Trusted Manufacturers all necessary rights to use (on a non-exclusive, royalty-free
                                         and license-fee free basis) the Background Technology and Project Technology to further
                                         Develop the Platform, and to Manufacture Products for use in the Field in the Affected
                                         Territory in accordance with the CEPI Production Timescale and in the quantities reasonably
                                         likely to be necessary in the event of an Outbreak or risk of Outbreak in the Field and
                                         at a cost of goods in line with the methodology to determine pricing obligations set
                                         out in the CEPI Equitable Access Policy;

 

    18

     

    

 

		(ii)	provide
                                         the Technology Transfer Materials to the Trusted Manufacturers and ensure that such Technology
                                         Transfer Materials are kept up to date, in particular, at each date on which the Partner
                                         requests any payment from CEPI, on the occurrence of one or more Conditions Precedent
                                         and on termination or expiration (for whatever reason) of this Agreement;

 

		(iii)	at
                                         the request of CEPI, enable Trusted Manufacturers to establish a warm base for the further
                                         Development of the Platform, and Manufacturing of Products for use in the Field in the
                                         Affected Territory;

 

		(iv)	collaborate
                                         with public sector agencies to use the Platform to Manufacture Products for use in the
                                         Field in the Affected Territory in accordance with the CEPI Production Timeframe in the
                                         quantities reasonably likely to be necessary and at a cost of goods in line with the
                                         methodology to determine pricing obligations set out in the CEPI Equitable Access Policy,
                                         in particular before any Outbreak or when there is Risk of Outbreak; and

 

		(v)	provide all necessary commercially
                                         reasonable support to the Trusted Manufacturers to facilitate the foregoing.

 

		7.7	Partner
                                         nominees for Trusted Manufacturers. Upon CEPI’s request, Partner will use Reasonable
                                         Efforts to notify CEPI of suitable Trusted Manufacturers for appointment by CEPI.

 

		7.8	CEPI
                                         nominees for Trusted Manufacturers.CEPI may nominate by notice in writing to Partner
                                         Third Parties as suggested Trusted Manufacturers. The Partner shall consider any Third
                                         Parties nominated by CEPI as potential Trusted Manufacturers in good faith. Where a Third
                                         Party nominated by CEPI is not acceptable to the Partner on reasonable grounds (including
                                         commercial grounds), the Partner shall notify CEPI promptly of its decision and the reasonable
                                         grounds and CEPI shall not appoint such Third Party as a Trusted Manufacturer.

 

		7.9	Additional
                                         Trusted Manufacturers. Subject to specific Additional Work Packages, CEPI has the
                                         right during the Project Term to pursue the appointment of additional Trusted Manufacturers
                                         where such additional capacity is necessary or useful to:

 

		7.9.1.	develop
                                         and/or increase Manufacturing capacity for Products for use in the Field in the Affected
                                         Territory to satisfy demand or likely demand;

 

		7.9.2.	develop
                                         and provide warm base Manufacturing capacity for emergency planning and contingency planning;

 

		7.9.3.	Manufacture
                                         emergency stockpiles of Products for use in the Field in the Affected Territory.

 

Partner
shall consider CEPI’s requests for additional Trusted Manufacturers in good faith and shall within [*****] of receipt of
such request notify CEPI in writing whether the Partner agrees or declines to support the appointment of additional Trusted Manufacturers
by CEPI together with the grounds for its decision.

 

		7.10	Disputes as to Trusted
                                         Manufacturers. In the event that the Parties are unable to reach agreement on the
                                         identity, number and/or necessary aggregate capacity of Trusted Manufacturers, the matter
                                         shall be resolved in accordance with the dispute resolution procedure set out in Clause
                                         22.

 

    19

     

    

 

		7.11	Partner reporting and
                                         compliance: Subject to specific Work Packages,Partner shall provide the following
                                         reports, notifications and samples to CEPI:

 

		7.11.1.	Financial
                                         reports. The Partner shall make the reports required under Clause 3 in accordance
                                         with the terms thereof.

 

		7.11.2.	Project
                                         Technology. The Partner shall ensure that the Project Lead promptly notifies JMAG
                                         and CEPI in writing of all Project Technology, and if required by CEPI, provides any
                                         assay or animal model for testing by a neutral Third Party acceptable to both CEPI and
                                         the Partner. The Partner shall share all Data and results with CEPI and the JMAG in as
                                         close to real-time as possible.

 

		7.11.3.	Patents.
                                         Partner shall inform the JMAG about patent applications filed for Project Technology.

 

		7.11.4.	Epidemiology.
                                         Partner agrees to make data generated pursuant to clinical trials in the Field that are
                                         relevant to the epidemiology of any disease in the Field publicly available within [*****]
                                         of the generation of such data.

 

		7.11.5.	Quarterly
                                         Reports. Partner shall provide Quarterly Reports to CEPI within [*****]
                                         of the end of each Project quarter. 

 

		7.11.6.	Safety
                                         Issues. The Partner shall notify CEPI and relevant JMAG members immediately by email
                                         (with receipt acknowledgement) as well as in writing in accordance with Clause 21.9:

 

		(i)	on
                                         receipt of any information that raises any material concerns regarding safety or efficacy
                                         of Product or the Platform;

 

		(ii)	where
                                         any data relating to a Product discloses a serious adverse event;

 

		(iii)	where
                                         a serious adverse event is suspected;

 

		(iv)	on
                                         the occurrence of a serious adverse event, serious adverse reaction, or any other material
                                         safety signal;

 

		(v)	of
                                         any Product recalls; and

 

		(vi)	of
                                         any recommendations from the data safety monitoring board for a clinical trial of a Product
                                         to end a clinical trial;
	 	 	 
	 	(together, the “Safety Issues”).

 

		7.11.7.	Pharmacovigilance.
                                         The Partner shall notify CEPI promptly in writing of any relevant event under any pharmacovigilance
                                         activities;

 

    20

     

    

 

		7.11.8.	Insurance.
                                         The Partner shall:

 

		(i)	provide
                                         CEPI with a copy of each insurance policy and certificate referred to in Clause 18.9
                                         annually on renewal; and

 

		(ii)	notify
                                         CEPI of any claims made under the insurance policies referred to in Clause 18.9 during
                                         the Project Term and for at least the duration of any applicable statutory period of
                                         limitation afterwards.

 

		7.11.9.	Equitable
                                         Access. Subject to Work Packages, Partner shall provide the following to CEPI to
                                         the extent not already included in the reports and information provided by the Partner
                                         to CEPI:

 

		(i)	progress
                                         report on the scale-up of the Platform for Manufacturing and a good faith estimate of
                                         the cost of the scale-up where such scale-up is necessary;

 

		(ii)	progress
                                         report on the scale-up of Manufacturing of Project Vaccine for use in the Field to fulfill
                                         any requirements of an Approved Regulatory Authority for the grant of marketing approval
                                         for such Project Vaccine for use in the Field in the Affected Territory;

 

		(iii)	progress
                                         reports on submissions to Regulatory Authorities for a Platform Confirmation or plans
                                         to do the same;

 

		(iv)	a
                                         good faith estimate of the number of doses of each Project Vaccine for use in the Field
                                         the Partner and/or Trusted Manufacturers are capable of producing, using the Platform
                                         and dates by when Partner estimates such volume will be achieved;

 

		(v)	a
                                         good faith estimate of Cost of Goods of doses of each Project Vaccine for use in the
                                         Field for both the investigational stockpile and any additional doses; and

 

		(vi)	the
                                         documents and information any estimates are based on together with any information on
                                         any factors that may impact the cost of each Project Vaccine use in the Field.

 

		7.11.10.	Partner
                                         Funder Requirements. The Partner shall notify CEPI promptly of any commitments made
                                         by Partner to other funders, such as Gates, for example, that arise or otherwise become
                                         applicable after the Effective Date and may have an impact on CEPI’s ability to
                                         utilize Project Technology in the event of an Outbreak or risk of an Outbreak and provide
                                         an informational copy of such commitments to CEPI.

 

		7.11.11.	Publication
                                         of details of clinical trials under the Project. The Partner shall publish details
                                         of any clinical trial under the Project on a publicly accessible clinical trials register
                                         as required under law and, as applicable, prior to the commencement of patient recruitment
                                         for such clinical trial, and shall provide to CEPI evidence of such publication within
                                         [*****] of the same.

 

		7.11.12.	Publications.
                                         The Partner shall ensure that the Project Lead furnishes CEPI with a copy of any proposed
                                         publication or presentation which relates to Project Technology at least [*****] in advance
                                         of the submission of such proposed publication or presentation to a journal, editor or
                                         publication.

 

    21

     

    

 

		7.11.13.	Open
                                         Access. A copy of the final manuscript of all research publications, journal articles,
                                         scholarly monologues and book chapters that relate to any Work Package of the Project
                                         must be deposited into PubMed Central (or Europe PubMed Central) or otherwise made freely
                                         available upon acceptance for publication or immediately after the publisher’s
                                         official date of final publication. All peer-reviewed published research funded, in whole
                                         or in part, by CEPI shall be published in accordance with the following requirements
                                         of Gates: https://www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy.

 

		7.11.14.	Open
                                         Data. The Partner shall publicly share Data and results (including negative results)
                                         arising from the CEPI funding as close to real time as possible in accordance with CEPI’s
                                         Transparency Policy and customary research publication norms. The Partner shall share
                                         its Data through an easily discoverable public route (website or system) which includes
                                         a metadata description, where patient privacy is upheld, and the system follows a request-for-information
                                         approach (where requests are fulfilled subject to an independent review and approval
                                         step). If, according to a CEPI policy, Partner Know-How is to be published such shall
                                         only occur, provided such Partner Know-How does not contain any Background Technology
                                         of the Partner, or Improvements to Background Technology of the Partner, and provided
                                         the JMAG has made a decision on this beforehand, taking the Partner’s reasonable
                                         concerns into account.

 

		7.11.15.	Regulatory Filings.
                                         Subject to specific Work Packages the Partner shall regularly update the JMAG on Regulatory
                                         Filings and submissions relating to the Platform and the Project Vaccine for use in the
                                         Field and put copies of the following on the JMAG electronic archiving service in a timely
                                         manner:

 

		(i)	all
                                         submissions to Regulatory Authorities and Regulatory Filings in respect of the Platform
                                         and Project Vaccine for use in the Field together with all Data included or referenced
                                         therein (other than ministerial submissions that do not involve safety or efficacy issues);

 

		(ii)	documents
                                         and information exchanged between any Regulatory Authority and the Partner relating to
                                         the Platform and/or Project Vaccine for use in the Field;

 

		(iii)	Master Files for Product
                                         Vaccines for use in the Field; and

 

		(iv)	the
                                         equivalent of a Master File in relation to the Platform.

 

The
provisions in this Clause 7 shall apply mutatis mutandis to Additional Work Packages and Additional Work Package Statements.

 

		8.	OUTBREAK
                                         AND RISK OF OUTBREAK IN THE FIELD

 

		8.1	Notification
                                         of Outbreak or Outbreak risk. CEPI shall notify Partner if there is an Outbreak in
                                         the Field or risk of an Outbreak in the Field.

 

    22

     

    

 

		8.2	During
                                         or after the Project where Outbreak or risk of an Outbreak can be addressed by a Project
                                         Vaccine: On receipt of such notice, subject to the respective Work Packages, the
                                         Work Package Statements and the Work Package Budgets the Partner agrees to make Reasonable
                                         Efforts to:

 

		8.2.1.	continue
                                         the Development, and Manufacturing the Project Vaccine for use in the Field in the Affected
                                         Territory in accordance with the existing or mutually agreed upon IPDP and Work Package
                                         Statements;

 

		8.2.2.	Manufacture
                                         the Project Vaccine for use in the Field in the Affected Territory in accordance with
                                         the CEPI Production Timeframe and in the quantities reasonably likely to be necessary
                                         and at a Cost of Goods in line with the methodology to determine pricing obligations
                                         set out in the CEPI Equitable Access Policy;

 

		8.2.3.	establish
                                         directly or to enter into an agreement with CEPI, a public sector agency or another Third
                                         Party, for the supply of Project Vaccine for use in the Affected Territory;

 

		8.2.4.	at
                                         the request of CEPI, agree in good faith with CEPI how the Development, and Manufacturing
                                         of the Project Vaccine can be accelerated and the amount of any additional funding necessary
                                         for such acceleration; and

 

		8.2.5.	make
                                         the Partner Contribution in accordance with the Work Package Statements.

 

		8.3	When
                                         an Outbreak or risk of an Outbreak Cannot be Addressed by a Project Vaccine: During
                                         the Initial Project Term and for [*****] thereafter where an Outbreak or risk of Outbreak
                                         in the Field cannot be addressed by a Project Vaccine or other Product Developed subject
                                         to an Additional Work Package, CEPI may notify Partner of its interest to develop such
                                         other Product, and CEPI and Partner may agree that Partner either develops such Product,
                                         or utilizes the RNA Optimizer Toolkit to assist CEPI to develop a candidate vaccine against
                                         that pathogen in the Field and to produce a vaccine stockpile, in each case pursuant
                                         to an Additional Work Package to be negotiated in good faith and agreed upon.

 

		8.3.1.	If
                                         Partner declines to enter into such agreement to develop Product, and subject to Partner’s
                                         obligations under Clause 8.3.2 below, then CEPI has the right to develop and stockpile
                                         such Products for potential use in the Field and to have such Product Manufactured by
                                         a Third Party in accordance with the Public Health License under Clause 11 below.

 

		8.3.2.	Upon
                                         CEPI’s notice in accordance with this Clause 8.3.2, Partner agrees to use Reasonable
                                         Efforts to submit optimized antigen nucleotide sequences utilizing the RNA Optimizer
                                         Toolkit for up to [*****] specified pathogens (based on amino acid sequences of such
                                         antigens provided by CEPI) under Additional Work Packages within the Field and during
                                         the Initial Project Term and for [*****] thereafter in order for CEPI to start its own
                                         product development. Partner agrees to provide up to [*****] optimized antigen nucleotide
                                         sequences per specified pathogen. If Partner agrees to develop another Product, such
                                         Product shall count against such [*****] pathogens above. For the avoidance of doubt
                                         regarding the scope of these activities, the Parties shall prepare an Additional Work
                                         Package that clarifies the specifications of these activities. For clarity, Partner will
                                         not be required to undertake any further development activities with respect to a Product,
                                         and CEPI with other partners will solely be responsible to advance the candidate Product
                                         for emergency use authorization or other marketing approval, such as, for example, pre-clinical
                                         studies.

 

    23

     

    

 

		8.3.3	CEPI
                                         will give Partner a Partner Right of First Refusal to Manufacture a Product developed
                                         pursuant to the foregoing Clause 8.3.2 on the Platform, subject to an Additional Work
                                         Package to be negotiated between the Parties in good faith and agreed upon setting out
                                         the activities to be conducted, Milestone Criteria, Milestone Dates, Work Package Budget,
                                         CEPI funding and the Partner Contribution. If the Partner declines to carry out such
                                         activities:

 

		(i)	CEPI may exercise the Public
                                         Health License and the activities shall be carried out by Trusted Manufacturers; and

 

		(ii)	the Partner shall comply
                                         with the provisions of Clause 12.

 

If
the Partner agrees to carry out the activities, but the Parties are unable to reach agreement by the deadline, or are unable to
agree the Additional Work Package Statement within [*****] of CEPI’s receipt of the Partner’s written notice referred
to above, the terms submitted by CEPI will apply.

 

		9.	CLINICAL
                                         TRIALS.

 

		9.1	Clinical
                                         trials under the Project. Subject to specific Work Packages where any Work Package
                                         includes a clinical trial, the Partner must:

 

		9.1.1.	be
                                         the sponsor of the clinical trial (unless CEPI and the Partner otherwise agree in writing);

 

		9.1.2.	ensure that the clinical
                                         trial is conducted in accordance with GCP;

 

		9.1.3.	be
                                         responsible for obtaining and maintaining all Regulatory Approvals (including ethical
                                         committee approvals) necessary or reasonably useful for the conduct of the clinical trial
                                         and appropriate clinical trial insurance cover;

 

		9.1.4.	establish
                                         a trial steering committee (TSC) comprised solely of members who are independent of the
                                         Partner and who are not involved in the clinical trial. The TSC shall approve the clinical
                                         trial protocol and monitor the progress of the clinical trial, including any changes
                                         to the protocol;

 

		9.1.5.	notify CEPI in writing
                                         immediately of the occurrence of any Safety Issues;

 

		9.1.6.	obtain or have obtained
                                         from each subject in the clinical trial, prior to enrollment and in accordance with all
                                         applicable laws and regulations, and as a condition of that clinical trial subject’s
                                         participation in the clinical trial, his or her informed consent to;

 

		9.1.7.	to the extent legally
                                         permitted, give direct access to his or her medical records;

 

		9.1.8.	to
                                         the extent legally permitted, process Data relating to him or her and to the movement
                                         of that Data to other countries, including countries outside of the European Economic
                                         Area; and

 

    24

     

    

 

 

		9.1.9.	to
                                         the extent legally permitted, transfer such Data to the Partner, CEPI and/or Trusted
                                         Manufacturer(s) and the use of such Data in obtaining marketing approval and/or Platform
                                         Confirmation.

 

		9.2	Clinical
                                         trial data. Subject to specific Work Packages with respect to each clinical trial
                                         under the Project:

 

		9.2.1.	the
                                         Partner shall procure that the Data is complete and include all completed case report
                                         forms and all other clinical trial documentation required to be in the possession of
                                         a clinical trial sponsor by Article 15(5) of Directive 2001/20/EC, Article 16 of Directive
                                         2005/28/EC or other relevant applicable law;

 

		9.2.2.	a
                                         CEPI representative or nominee shall have the right (except for any matters which should
                                         remain blinded to CEPI in the interests of the integrity of the clinical trial) to:

 

- attend meetings
of the TSC and the data safety monitoring board (DSMB) for the clinical trial as an observer;

 

- receive all
papers that a member of the TSC or DSMB would be entitled to receive; and

 

- attend TSC
or DSMB meetings by telephone or other electronic means rather than in person.

 

		9.3	Samples.
                                         CEPI may engage one or more neutral external Third Party laboratories or Third Party
                                         collaborators (“Assessors”) to perform additional testing (at CEPI’s
                                         cost) on biological samples in order to provide CEPI with directly comparable evaluations
                                         of similar vaccines produced by CEPI’s portfolio of vaccine platforms. In order
                                         to maintain appropriate blinding, CEPI may, in its sole discretion and at its own cost,
                                         also engage certain neutral Third Party entities to transport the samples from Partner
                                         to the Assessor as well as other services, for example, addressing import/export issues
                                         or documentation for biological samples (the “Transfer Agent”). The results
                                         of the testing, analysis, meta-analysis or other assessments will be subject to the confidentiality
                                         obligations under this Agreement. Upon request, CEPI will provide Partner with data or
                                         other assessments it receives from the Assessors regarding Partner’s own Project
                                         Vaccines, Products and/or Platforms. To enable CEPI to conduct such testing to the extent
                                         available, Partner agrees to:

 

		-	provide
                                         CEPI’s designated Assessor an agreed number of doses of the Project Vaccines, representative
                                         of the final drug product, for animal immunogenicity studies;

 

		-	provide
                                         CEPI’s designated Assessor an agreed number of doses of the Project Vaccines, representative
                                         of the final drug product, for animal challenge studies;

 

		-	provide
                                         CEPI’s designated Assessors (either directly or through the Transfer Agent) with
                                         agreed volumes of biological samples (e.g. serum, PBMCs) from human subjects vaccinated
                                         with the Project Vaccines in Phase 1 clinical trials at specified timepoints agreed with
                                         CEPI for immunology testing;

 

		-	provide
                                         CEPI’s designated Assessors (either directly or through the Transfer Agent) with
                                         an agreed number of samples from clinical studies under the Project for use in future
                                         research carried out by or on behalf of CEPI in the Field;

 

		-	include language in the
                                         informed consent forms used in connection with the collection of the biological samples
                                         described herein, granting permission for such samples and any associated data (both
                                         duly anonymized) to be used for the purposes indicated in this Clause 9 and also that
                                         all such informed consent forms have been approved by any and all appropriate ethical
                                         committees or institutional review boards; and

 

		-	obtain
                                         informed consent from the human subjects vaccinated with the Project Vaccines in clinical
                                         trials that gives permission for the collection and use of such samples and associated
                                         data (duly anonymized and, upon CEPI’s request, blinded) for the purposes indicated
                                         in this Clause 9, and also that all such informed consents satisfy the requirements of
                                         any and all appropriate ethical committees or institutional review boards.

 

    25

     

    

 

Any
samples to be transferred or exported by or on behalf of the Partner (either directly to the Assessor or via a Transfer Agent)
from a clinical trial site or an Affected Territory must be transferred and/or exported pursuant to the terms and conditions of
a suitable to-be-agreed-upon material transfer agreement (for example, the Draft WHO Blueprint MTA or similar) to be entered into
between the Partner and the Assessor (and the Transfer Agent if appropriate) in addition to any other applicable laws and regulations.
Partner undertakes to ensure that all requisite informed consent documentation allowing the provision, transportation, use and
analysis of relevant samples have been obtained; furthermore, Partner will have obtained any and all ethical committee or institutional
review board approvals necessary prior to its undertakings pursuant to this Clause 9.

 

		9.4	Data.
                                         CEPI may engage one or more Assessors to perform certain assessments and/or meta-analyses
                                         of data (at CEPI’s cost) to provide CEPI with directly comparable assessments of
                                         equivalent vaccines produced by CEPI’s portfolio of vaccine platforms. The results
                                         of the data analysis or other assessments will be subject to the confidentiality and
                                         data protection obligations and the limitations of the Public Health License under this
                                         Agreement. Upon request, CEPI will provide the results of such data analysis as regards
                                         their own data to the Partner. To enable CEPI or its Assessors to conduct such analyses,
                                         subject to specific Work Packages, the Partner agrees to take Reasonable Efforts as follows:

 

		9.4.1.	to
                                         provide data or other information generated by Partner under this Agreement to CEPI’s
                                         designated Assessor as CEPI shall request, including without limitation, data regarding
                                         CMC, formulation or the results of any of its pre-clinical or clinical trials (duly anonymized
                                         and, upon CEPI’s request, blinded);

 

		9.4.2.	to
                                         provide CEPI’s designated Assessor with other data (duly de-identified and, upon
                                         CEPI’s request, blinded) from the Development as CEPI may reasonably request in
                                         order to conduct comparative assessments and meta-analyses thereof;

 

		9.4.3.	to
                                         include language in the informed consent forms used in connection with the use of data
                                         or the collection of samples from which such data is derived, granting permissions for
                                         such data (duly de-identified) to be used for the purposes indicated in this Clause 9,and
                                         also that all such informed consent forms have been approved by any and all appropriate
                                         ethical committees or institutional review boards; and

 

		9.4.4.	to
                                         obtain informed consent from the human subjects vaccinated with the Project Vaccines
                                         in clinical trials that gives permission for the use of data (duly de-identified and,
                                         at CEPI’s request, blinded) and for the collection of samples from which data is
                                         derived (ensure that all requisite informed consent documentation allowing the provision,
                                         transportation, use and analysis of data by CEPI or its designated Assessors as indicated
                                         in this Clause 9; and also that all such informed consents satisfy the requirements of
                                         any and all appropriate ethical committees or institutional review boards.

 

The provisions
in this Clause 9 shall apply mutatis mutandis to Additional Work Packages and Additional Work Package Statements.

 

		10.	COLLABORATORS
                                         AND SUB-CONTRACTORS.

 

		10.1	Contractors
                                         and Sub-Contractors. Where the Partner wishes to use a Third Party collaborator or
                                         Sub-Contractor to conduct any specific part of the Project or a Work Package assigned
                                         to the Partner and to be delegated to such party (hereinafter the “Sub-Contractor”),
                                         it shall seek the consent of the JMAG which shall not be unreasonably withheld, conditioned
                                         or delayed, prior to entering into any agreement with such Sub-Contractor(s), unless
                                         (x) Partner has a standing contractual relationship with such Sub-Contractor, such Sub-Contractor
                                         is providing services for Partner also in the context of other projects; or (y) such
                                         Sub-Contractor is explicitly named, with full identification details provided, including
                                         registered address and, where relevant, company number, along with a clear explanation
                                         of the role such Sub-Contractor shall perform and what Contractor Results and Deliverables
                                         they shall produce in the Work Package Statement; and shall ensure that:

 

    26

     

    

 

		10.1.1.	the
                                         Sub-Contractor grant rights to the Partner to use any Contractor Results and Deliverables
                                         generated by the Sub-Contractor;

 

		10.1.2.	a
                                         suitable written Sub-Contract agreement is put in place between the Partner and the Sub-Contractor.
                                         For the avoidance of doubt, CEPI must approve all Sub-Contractors that:

                                                                                                   (i)
                                         will be allocated CEPI funds in an amount greater than USD $ [*****] per year to conduct
                                         any part of the Project;

                                                                                (ii)
                                         will conduct a clinical trial; or

                                                                                (iii)
                                         will have rights to Manufacture, distribute or otherwise commercialize a Product;

 

		10.1.3.	the
                                         agreement with the Sub-Contractor is consistent with both the Work Package approach to
                                         the Project and the Milestones, Milestone Criteria, Milestone Dates, Stage Gate Criteria
                                         and Stage Gate Dates for the applicable Work Package(s), and - with respect to agreements
                                         or work orders with Sub-Contractors, which are concluded specifically to perform the
                                         Work Packages, - the termination provisions are consistent with this Agreement so that
                                         such subcontracting agreement or work order automatically terminates or is capable of
                                         termination on termination of this Agreement or termination of any Work Package, and
                                         prohibits the Sub-Contractor from sub-contracting its obligations; and

 

		10.1.4.	the
                                         agreement with the Sub-Contractor complies with the provisions of this Agreement required
                                         to be imposed on Sub-Contractors or contains provisions that enable the Partner to comply
                                         with its obligations under this Agreement including this Clause 10, Clause 3 (Financial
                                         Records and audit requirements) Clause 4 (Project Standards, Records and Management),
                                         Clause 5 (Project Management and Oversight), and Clause 17 (Confidentiality).

 

		10.2	Partner
                                         Affiliates. The Partner may perform its obligations under this Agreement through
                                         an Affiliate. The Partner shall be responsible for the acts and omissions of the Affiliate
                                         as if they were the Partner’s own acts and omissions.

 

The provisions in this
Clause 10 shall apply mutatis mutandis to Additional Work Packages and Additional Work Package Statements.

 

		11.	PUBLIC
                                         HEALTH LICENSE

 

		11.1	The
                                         Partner hereby grants to CEPI with effect from the Effective Date, a non-exclusive, worldwide,
                                         royalty-free and license-fee free license (except in respect of the sharing of Commercial
                                         Benefits pursuant to Clause 13) under the Background Technology and Project Technology
                                         to:

 

		11.1.1.	develop the Platform
                                         for use in the Field via Trusted Manufacturers;

 

		11.1.2.	Manufacture and market
                                         Product for use in the Field in the Affected Territory via Trusted Manufacturers;

 

		11.1.3.	Develop the Project
                                         Vaccine;

 

		11.1.4.	compare
                                         and contrast the relative advantages and disadvantages of the Platform and alternative
                                         platforms for use in the Field; and

 

		11.1.5.	compare
                                         and contrast the relative advantages and disadvantages of Product for use in the Field
                                         in the Affected Territory against the advantages and disadvantages of alternative equivalent
                                         products for use in the Field in the Affected Territory;

 

(together,
the “Public Health License”); provided however that CEPI may not exercise the rights granted under the Public
Health License unless and until the occurrence of one or more Conditions Precedent.

 

    27

     

    

 

		11.2	Covenant
                                         not to sue. During the term of the Public Health License under this Clause 11, Partner
                                         shall not sue CEPI, or any Third Party which holds a permitted sublicense to the Background
                                         Technology from CEPI or a sublicensee of CEPI, for infringement of any Technology Controlled
                                         by the Partner, by developing Products in the Field and for the Affected Territory, even
                                         if such Technology is not part of the Background Technology.

 

		11.3	Third
                                         Party license fees. To the extent the Public Health License triggers payments to
                                         Third Parties, including license fees and royalty payments, CEPI shall assume these payment
                                         obligations, and reimburse any payments made by Partner for such use.
	 	 	 

		11.4	No implied licenses.
                                         Except for the rights and licenses granted to CEPI, the Partner retains all rights under
                                         its Technology.

 

		12.	CONDITIONS
                                         PRECEDENT AND EXERCISE OF THE PUBLIC HEALTH LICENSE

 

		12.1	Exercise
                                         of Public Health License. CEPI may exercise the Public Health License by notice in
                                         writing to the Partner on the occurrence of one or more of the events set out below (each
                                         a “Condition Precedent” and together the “Conditions Precedent”):

 

		12.1.1.	except where failure
                                         is due to reasonable scientific, safety or regulatory issues, the Partner:

 

		(i)	materially
                                         fails to Develop the Platform and/or the Project Vaccines in accordance with the Work
                                         Package Statements or Additional Work Package Statements as they relate to Products and/or
                                         the IPDP; or

 

		(ii)	fails
                                         to use Reasonable Efforts to satisfy any Milestone Criteria or Stage Gate Criteria by
                                         the relevant Milestone Date or Stage Gate Date; and in each case, fails to remedy the
                                         situation within [*****] of the receipt by Partner of notice from CEPI identifying the
                                         failure and requiring its remedy (or as otherwise as agreed in writing by the Parties);

 

		12.1.2.	CEPI terminates the
                                         Agreement in accordance with Clause 19.2 below.

 

		12.1.3.	in the event of an
                                         Outbreak or Outbreak risk:

 

		(i)	the
                                         Partner does not exercise the Partner Right of First Refusal or declines to enter into
                                         an agreement under Clause 8.3.1;

 

		(ii)	the
                                         Partner informs CEPI that it will not be able to Develop and Manufacture Project Vaccine
                                         in accordance with the CEPI Production Timeframe, in sufficient quantities and at an
                                         appropriate cost given the nature and health implications of the Outbreak or Outbreak
                                         risk;

 

		(iii)	the
                                         Partner’s Development and Manufacture of Project Vaccine for use in the Field does
                                         not achieve the CEPI Production Timeframe, in appropriate quantities and/or at an appropriate
                                         cost given the nature and health implications of the Outbreak or Outbreak risk; or

 

		(iv)	CEPI,
                                         in good faith, based on actual non-performance or late performance has reason to assume
                                         that the Partner is unable or unwilling to Develop or Manufacture Project Vaccine for
                                         use in the Field in sufficient quantities in accordance with the CEPI Production Timeframe
                                         and at an appropriate cost given the nature and health implications of the Outbreak or
                                         Outbreak risk;

 

    28

     

    

 

		12.1.4.	if
                                         by the date [*****] following successful completion of the Project the Cost of Goods
                                         for the Project Vaccines for use in the Field exceeds the level public service agencies
                                         agree is affordable based on objective economic criteria to be determined between the
                                         Parties for use in the Affected Territory;
	 	 	 

		12.1.5.	if
                                         by the date [*****] following successful completion of the Project, the Cost of Goods
                                         for a specific Project Vaccine for use in the Field exceeds the level public service
                                         agencies agree is affordable based on objective economic criteria to be determined between
                                         the Parties for use in the Affected Territories;

 

		12.1.6.	where
                                         one or more Project Vaccine becomes subject to a pattern of serious adverse events (as
                                         defined in the ICH Guidelines) or either Party receives notice from a Regulatory Authority,
                                         independent review committee, a data safety monitoring board or another similar clinical
                                         trial or post-marketing body alleging significant concern regarding a patient safety
                                         issue, in each case in which CEPI, in good faith, reasonably believes would seriously
                                         impact the long-term viability of one or more of the Project Vaccines for use in the
                                         Field;

 

		12.1.7.	there
                                         are material Safety Issues and/or quality issues in relation to use of the Platform that
                                         will seriously impact the long-term viability of the Platform; and

 

		12.1.8.	on
                                         termination of the Agreement where the Partner is the Defaulting Party.

 

		12.2	Disputes
                                         relating to the occurrence of a Conditions Precedent. In the event that the Parties
                                         dispute the occurrence one or more of the Conditions Precedents, the matter shall be
                                         resolved in accordance with the dispute resolution procedure set out at Clause 22 provided
                                         however that any arbitration decision shall be made within [*****] of the date of the
                                         reference to arbitration. Whilst the dispute is subject to arbitration, on the occurrence
                                         of an Outbreak in the Field and/or risk of an Outbreak in the Field, CEPI shall be entitled
                                         to exercise the Public Health License solely to have Developed Project Vaccines, and
                                         to have Manufactured and marketed Product via the Trusted Manufacturer for use in the
                                         Field in the Affected Territory to address the Outbreak or Outbreak risk. In such event,
                                         the Partner shall use all reasonable endeavors to give assistance to CEPI and/or the
                                         Trusted Manufacturer(s) including: (i) transferring to the Trusted Manufacturer(s) all
                                         Data, Materials, Confidential Information and Regulatory Filings (including the Master
                                         File) necessary or desirable for CEPI to conduct such Development of Products including
                                         Project Vaccines, Manufacturing and marketing; and (ii) executing any necessary documents.

 

		12.3	Effects
                                         of exercise of the Public Health License. On exercise of the Public Health License,
                                         CEPI, after consultation with Partner, shall have the discretion to make any reasonable
                                         decisions in relation to the Development of the Platform for use in the Field, the Development
                                         of Products including Project Vaccine, Manufacturing and marketing of the Product for
                                         use in the Field in the Affected Territory by the Trusted Manufacturer(s). The Partner
                                         shall use all reasonable endeavors to give assistance to CEPI and/or the Trusted Manufacturer(s)
                                         in relation to such Manufacturing for use in the Field in the Affected Territory including
                                         executing any necessary documents.

 

		12.4	Rights
                                         of action. Following exercise of the Public Health License, CEPI shall have the right
                                         to take all such action as it shall consider necessary or appropriate at its discretion
                                         and expense to bring or defend an action on behalf of the Partner in relation to Project
                                         Vaccine for use in the Field and use of the Platform in the Field. The Partner shall
                                         (at CEPI’s cost) provide all reasonable assistance to CEPI as CEPI may request
                                         in relation to such action, including granting CEPI the right to bring an action in the
                                         name of the Partner (if necessary).

 

    29

     

    

 

		12.5	Release of Technology
                                         Transfer Materials. On the exercise of the Public Health License, the Partner shall
                                         release immediately the Technology Transfer Materials.
	 	 	 

		12.6	Contracts.
                                         Subject to applicable confidentiality obligations, the Partner shall provide CEPI
                                         with copies of all Sub-Contracts which relate to the Development of the Platform for
                                         use in the Field, the Development of Project Vaccine, and the Manufacturing of Product
                                         in the Field and access to which is required for the Third Party Manufacture within [*****]
                                         of exercise of the Public Health License. Provided that exercise of the Public Health
                                         License was not caused directly or indirectly by the Sub-Contractor and that Sub-Contractor
                                         is not then in breach, the Partner shall use all Reasonable Efforts, at CEPI’s
                                         reasonable request, to facilitate the conclusion of a direct contractual relationship
                                         between the Sub-Contractor and CEPI or Trusted Manufacturer to the extent required for
                                         CEPI or its nominee.

 

		12.7	Clinical
                                         trials after exercise of Public Health License. Where CEPI has exercised the Public
                                         Health License and a clinical trial of Project Vaccines/ Products for use in the Field
                                         is to be conducted, CEPI shall:

 

		12.7.1.	ensure that the clinical
                                         trial has an appropriate Sponsor;

 

		12.7.2.	comply
                                         with CEPI’s insurance obligations pursuant to Clause 18.10 and ensure appropriate
                                         clinical trial liability insurance cover for the clinical trial is in place;

 

		12.7.3.	ensure that the clinical
                                         trial is conducted in accordance with GCP;

 

		12.7.4.	ensure that all Regulatory
                                         Approvals (including ethical committee approvals) necessary or reasonably useful for
                                         the conduct of the clinical trial are obtained;

 

		12.7.5.	ensure
                                         that a trial steering committee (TSC) is established which shall approve the clinical
                                         trial protocol and monitor the progress of the clinical trial, including any changes
                                         to the protocol. The TSC shall only include members who are independent of CEPI and who
                                         are not otherwise involved in the clinical trial;

 

		12.7.6.	communicate
                                         to Partner in writing immediately the occurrence of any Safety Issues; and

 

		12.7.7.	ensure
                                         that, to the extent possible, prior to enrolment and in accordance with all applicable
                                         laws and regulations, and as a condition of that clinical trial subject’s participation
                                         in the clinical trial, each subject provides his or her informed consent -to the extent
                                         legally permitted - to:

 

		(i)	direct access to his or
                                         her medical records;

 

		(ii)	process
                                         Data relating to him or her and to the movement of that Data to other countries, including
                                         countries outside of the European Economic Area;

 

		(iii)	transfer
                                         of such Data to the Partner, CEPI and/or Trusted Manufacturer(s) and the use of such
                                         Data in obtaining marketing approval and/or Platform Confirmation; and

 

		(iv)	use of samples in accordance
                                         with Clause 9.3.

 

    30

     

    

 

		13.	COMMERCIAL
                                         BENEFITS ARISING FROM COMMERCIAL USE

 

		13.1	Commercial Use. In
                                         the event of any Commercial Use by Partner of Products, which are developed, Manufactured
                                         or commercialized by or on behalf of CEPI in the Field in an Affected Territory using
                                         Project Technology, the Partner shall:

 

		13.1.1.	notify CEPI promptly
                                         of such Commercial Use; and

 

		13.1.2.	comply
                                         with the CEPI Equitable Access Policy set out in the relevant CEPI Policy at Schedule
                                         10 with respect to such Products, and subject to Section 13.2 below.

 

		13.2	Commercial
                                         Benefits sharing agreement.The Parties shall agree in good faith how such Commercial
                                         Benefits (if any) are to be managed in a fair, equitable and proportionate manner, taking
                                         account the financial contribution of each of the Parties to the Background Technology
                                         and Project Technology being exploited, the public and philanthropic nature of the CEPI
                                         funding, any other non-repayable public or philanthropic financial contribution to the
                                         foregoing, the public benefit derived from the Commercial Use, and any private or ancillary
                                         benefit that may arise. The Parties shall execute a separate agreement implementing their
                                         good faith agreement on how such Commercial Benefits are to be managed in a fair, equitable
                                         and proportionate manner as of the Effective Date of this Agreement. For the avoidance
                                         of doubt, Commercial Benefits generated outside the Field and/or outside the scope of
                                         Clause 13.1 will not be shared between the Parties.

 

		13.3	Use
                                         of Product in Affected Territory Only. CEPI intends to take Reasonable Efforts to
                                         ensure that the Products will be utilized in the Affected Territory only and to prevent
                                         parallel imports of such Products into other countries, which efforts may include CEPI
                                         or its contractor or licensee placing an indication on the packaging of the Products
                                         that they are for use in countries of the Affected Territory only and are not to be exported
                                         into any other countries. If either Party becomes aware that parallel imports of such
                                         Products outside the Affected Territory are occurring, the Parties will inform each other
                                         and will cooperate in good faith to verify the circumstances and take such reasonable
                                         action as they mutually agree is necessary.

 

		14.	BACKGROUND
                                         TECHNOLOGY AND PROJECT TECHNOLOGY

 

		14.1	Background
                                         Technology. Partner shall have the right but not the obligation to prosecute, maintain
                                         and defend the patent rights which are part of the Background Technology.

 

		14.2	Ownership
                                         of Project Technology. Except as expressly provided below and to the extent feasible
                                         and legally possible, all Project Technology shall be either the property of the Partner
                                         or be licensed from Third Parties, and any patents in respect of Project Technology shall
                                         be applied for in the name of the Partner. The Partner shall procure that:

 

		14.2.1.	any
                                         Affiliate, Third Party collaborator, Third Party funder, co-owner or Sub-Contractor of
                                         the Partner shall assign all its right, title and interest in Project Technology promptly
                                         to the Partner to the extent Controlled and shall retain rights in the same to the extent
                                         stipulated under the agreement between Partner and Sub-Contractor
	 	 	 

		14.2.2.	it shall have in
                                         place contracts with those working on or funding all Work Packages of the Project to
                                         ensure that the Project Technology shall vest in the Partner and not with any members
                                         of staff individually. Where by local applicable law such rights do vest in individual
                                         members of staff, the Partner shall ensure that it has all rights to take assignment
                                         of all right title and interest in the same and the Partner shall bear the costs of any
                                         necessary contribution to such individual or other costs of assignment; and

 

    31

     

    

 

		14.2.3.	where
                                         a Partner has appointed NIH or another government entity or university as a Third Party
                                         Sub-Contractor and such government entity is required by law or otherwise to retain ownership
                                         of Contractor Results they have generated in the conduct of activities described in a
                                         Work Package Statement (“Government Results”), the Partner shall ensure
                                         that the government entity provides Partner with sufficient rights and license (including
                                         via option to license where the government entity is unable to provide licenses in advance
                                         of generation) to any such Government Results in order to enable the Partner or CEPI
                                         to further Develop the Platform and Develop and Manufacture Project Vaccines and Manufacture
                                         Products in accordance with the terms and conditions of this Agreement.

 

		14.3	Patent
                                         protection and Project Technology. The Partner has the rights but no obligation to
                                         take responsibility for seeking and maintaining protection for Project Technology at
                                         its sole cost, including the filing, prosecution, maintenance, extension and defense
                                         of any patent applications or patents in respect of Project Technology

 

		14.4	Infringement.
                                         The Partner shall immediately give notice to CEPI if it becomes aware of:

 

		14.4.1.	any
                                         infringement or suspected infringement or misappropriation of the Background Technology
                                         and/or Project Technology; and

 

		14.4.2.	any claim by a Third
                                         Party that an action carried out under the Project infringes the intellectual property
                                         or other rights of any Third Party.

 

		14.5	Rights
                                         of Action. Prior to the exercise of the Public Health License, the provisions of
                                         Clause 14.3 will apply and Partner will consult with CEPI about what action it should
                                         take. Where CEPI has exercised the Public Health License the provisions of Clause 12.3
                                         shall apply.

 

		14.6	Platform
                                         Improvements and/or Product Improvements. To the extent it is contractually able
                                         to do so, Partner shall ensure that it has the right to grant the Public Health License
                                         to CEPI in respect of future Platform Improvements and/or Improvements of the Product
                                         comprising Background Technology. To the extent that CEPI is contractually able to do
                                         so, CEPI hereby grants to Partner, and Partner hereby accepts, a non-exclusive, irrevocable,
                                         perpetual, worldwide license, sublicensable in multiple ties, to use the Improvements
                                         made by or on behalf of CEPI to the Product or to the Platform for any purposes inside
                                         and outside the Field. The undertakings herein shall be in force during the Project Term
                                         and for [*****] thereafter,

 

		15.	PROJECT
                                         TECHNOLOGY – EXPLOITATION

 

		15.1	Partner’s
                                         Undertakings. To the extent it is contractually able to do so, Partner shall obtain
                                         CEPI’s prior written consent before exploiting, or allowing a Third Party to exploit
                                         any of the Project Technology within the Field, provided the exploitation is in conflict
                                         with or goes against CEPI’s mission, the CEPI Policies or the provisions of this
                                         Clause.

 

		15.2	Right
                                         of Reference. The Parties grant each other a right of reference to the regulatory
                                         materials relating to the Platform and the Product for use in their respective fields
                                         of use.

 

    32

     

    

 

		16.	ANNOUNCEMENTS
                                         AND PUBLICATIONS

 

		16.1	Announcements

 

		16.1.1.	Except
                                         for announcements required by law or any competent regulatory authority, the Parties
                                         shall consult on and agree in writing upon the form of all press releases, publications
                                         and public announcements concerning this Agreement, the Project and the CEPI funding.

 

		16.1.2.	The
                                         Partner must include an acknowledgement of CEPI funding in a form approved by CEPI in
                                         advance in all press releases, publications or public announcements relating to the Project
                                         and the Platform and/or Product.

 

		16.1.3.	In accordance with
                                         the CEPI policies, a summary of the progress and outcomes of the Project, the terms and
                                         conditions of this Agreement, the name of the Partner and the Project Lead, and the amount
                                         of the CEPI funding and Partner Contribution will be published or otherwise disseminated
                                         to the public in an appropriate form.

 

		16.1.4.	Patent
                                         publications. Following publication of any patent in respect of the Project Technology,
                                         the Partner shall have the right to publish and reproduce any such publication freely
                                         with due acknowledgement of the sources including, where appropriate, sources of funding
                                         and the individuals and communities from whom data has been collected.

 

		17.	CONFIDENTIALITY

 

		17.1	Confidentiality
                                         Obligations. Subject to the provisions of this Clause 17, each Party undertakes that
                                         both during the Project Term and for a period of [*****] after its termination, it shall
                                         keep confidential and not disclose to any person any Confidential Information of the
                                         Party disclosed to or obtained by it in connection with this Agreement. Each Party shall
                                         take all reasonable security precautions in relation to the Confidential Information
                                         under its control. Where the Partner engages any Sub-Contractor, the Partner shall ensure
                                         that such Sub-CContractor is bound by confidentiality and non-use obligations which are
                                         at least as onerous as those set out in this Agreement. Each Party shall ensure that
                                         all staff and third parties to whom Confidential Information of the other Party is disclosed
                                         are:

 

		17.1.1.	informed of the provisions
                                         of Clause 17 of this Agreement; and

 

		17.1.2.	bound by confidentiality
                                         and non-use obligations at least as onerous as those herein.

 

		17.2	Exceptions.
                                         Clause 17.1 shall not apply to:

 

		17.2.1.	information
                                         which is or was already known to the receiving Party at the time of disclosure under
                                         this Agreement, as shown by the receiving Party’s written records, without any
                                         obligation to keep it confidential;

 

		17.2.2.	information
                                         which is independently developed by employees of the receiving Party who have not had
                                         access to the Confidential Information of the disclosing Party as evidenced by the receiving
                                         Party’s written records;

 

		17.2.3.	information
                                         which at the time of being disclosed or obtained by the receiving Party under this Agreement
                                         or at any time thereafter, is published or otherwise generally available to the public
                                         other than due to default by the receiving Party of its obligations hereunder;

 

    33

     

    

 

		17.2.4.	the
                                         disclosure of Confidential Information to a Party’s Affiliates officers, employees,
                                         staff, consultants or professional advisors on a need-to-know basis and in the case of
                                         the Partner, to collaborators and contractors pursuant to Clause 17.1 who are bound by
                                         confidentiality and non-use obligations at least as onerous as those herein;

 

		17.2.5.	the
                                         disclosure of information by either Party to the JMAG, Stage Gate Committee or any site
                                         visit group is permitted but is subject to the confidentiality obligations under this
                                         Clause 17;

 

		17.2.6.	the
                                         disclosure of information which is required to be disclosed by a competent Court or regulatory
                                         authority or otherwise by applicable law (including any requirements for disclosure under
                                         the Freedom of Information Act 2000), provided that where it is free to do so, the receiving
                                         Party shall give notice of such disclosure to the disclosing Party as soon as reasonably
                                         practicable; and/or

 

		17.2.7.	the
                                         disclosure of Partner’s Confidential Information by CEPI where such disclosure
                                         is expressly provided for in the terms of this Agreement (including where CEPI has exercised
                                         the Public Health License) and disclosure to any member of the CEPI Group and CEPI’s
                                         funders including but not be limited to the Financial Documents and the records referred
                                         to in Clauses 3 and 4 above.

 

		17.3	In
                                         recognition of CEPI’s mission, nothing in this Clause 17 shall prevent CEPI from
                                         using the Confidential Information, or comparing the Confidential Information to information
                                         already in its possession, in each case solely to inform its assessment of applications
                                         made to it for funding in furtherance of CEPI’s mission and other projects funded
                                         by it in furtherance of CEPI’s mission.

 

		18.	WARRANTIES,
                                         LIABILITY AND INSURANCE

 

		18.1	Warranties.
                                         On the Effective Date the Partner warrants to CEPI (subject to any matters disclosed
                                         in the Disclosure Letter that the warranties set out below (the “Warranties”)
                                         are true and correct and that the Partner is in compliance with the Warranties:

 

		18.1.1.	it has the requisite
                                         authority to enter into this Agreement;

 

		18.1.2.	it
                                         has full power and authority to assume all of its obligations and commitments under this
                                         Agreement;

 

 

    34

     

    

 

		18.1.3.	to
                                         its present knowledge and belief, it is the legal and beneficial owner and/or licensee
                                         of all right, title and interest in and to all Background Technology used in the Project
                                         at the time they are used;

 

		18.1.4.	save
                                         as disclosed in the Disclosure Letter, it does not, to its present knowledge, infringe,
                                         misappropriate or violate the intellectual property, privacy or publicity rights of any
                                         Third Party;

 

		18.1.5.	it
                                         has not granted any Third Party any right in respect of any Project Technology (other
                                         than in accordance with the terms of this Agreement), and has not charged or encumbered
                                         any of the same;

 

		18.1.6.	save
                                         as disclosed in the Disclosure Letter, to its present knowledge, the Background Technology
                                         and Project Technology are not subject to any claim, opposition, attack, assertion or
                                         other arrangements of whatever nature which may impugn upon the use, validity, enforceability
                                         or ownership of any such Technology, and there are no grounds or other circumstances
                                         which may give rise to the same;

 

		18.1.7.	save
                                         as disclosed in the Disclosure Letter, ownership of any equipment or Deliverables developed
                                         with CEPI funding, shall vest in the Partner;

 

		18.1.8.	it
                                         has not itself or through any of its staff, collaborators or Sub-Contractors, disclosed
                                         to any Third Party (other than under appropriate confidentiality obligations) any Confidential
                                         Information relating to the Project, nor is it obliged so to do;

 

		18.1.9.	to
                                         its present knowledge, other than under the Global Access Commitments Agreement with
                                         Gates dated February 13, 2015, no person has the right to call for the assignment of,
                                         grant of a license to it of or the right to any lien or encumbrance over any Background
                                         Technology or Project Technology under any option, grant or other agreement for use in
                                         the Field, nor is there any conditional or unconditional agreement or circumstance whereby
                                         such a right may arise;

 

		18.1.10.	to
                                         its present knowledge, no person has any right or claim to any payment or other compensation
                                         in respect of the use or exploitation of the Background Technology or Project Technology
                                         under this Agreement, except as set forth in pre-existing license agreements with Third
                                         Parties, reasonably redacted copies of which license agreements have been delivered to
                                         CEPI prior to the Effective Date or as set forth in license agreements under negotiation
                                         at the Effective Date that contemplate the execution of this Agreement, copies of the
                                         drafts of which have been delivered to CEPI prior to the Effective Date;

 

		18.1.11.	the
                                         Partner was the sponsor of all clinical trials from which Data was obtained;

 

		18.1.12.	the
                                         Partner will disclose to CEPI all relevant Safety Issues and adverse information in relation
                                         to the safety and efficacy of the Platform and Project Vaccine that come to its attention;

 

		18.1.13.	to
                                         its present knowledge the Partner has disclosed to CEPI all material communications with
                                         Regulatory Authorities, any ethical committee refusal to grant approval for a clinical
                                         trial, any suspension of a clinical trial, whether initiated by the sponsor, an ethical
                                         committee, a Regulatory Authority or an investigator, any action or recommendation of
                                         a data safety monitoring board to suspend the clinical trial, and all findings of any
                                         audit for a clinical trial for compliance with GCP relating to the Platform and Project
                                         Vaccine;

 

    35

     

    

 

		18.1.14.	to
                                         its present knowledge none of the Partner, its Affiliates, Sub-Contractors, nor any officer
                                         or employee of the foregoing has been debarred or is subject to debarment by a Regulatory
                                         Authority anywhere;

 

		18.1.15.	to
                                         its present knowledge, all Financial Documents were true, complete and accurate at the
                                         date of such document; and

 

		18.1.16.	all
                                         CEPI funding has been deposited in the designated bank account in the currency of US
                                         dollars in the name of the Partner and into which only the CEPI funding and interest
                                         earned on that money has been deposited.

 

		18.2	No
                                         implied warranties. Except as expressly provided in this Agreement, neither Party
                                         gives any warranties or makes any representations with respect to any of the Background
                                         Technology, the Project Technology, the Platform or any Products derived from them, or
                                         their fitness for any purpose.

 

		18.3	Obligation
                                         to inform. The Partner will use Reasonable Efforts to inform CEPI of any matter which
                                         it becomes aware of during the Project Term and which would have been subject of a disclosure
                                         under the Disclosure Letter, if it had been known on the Effective Date.

 

		18.4	Liability
                                         cap. Either Party’s maximum liability in aggregate to the respective other
                                         Party arising out of this Agreement shall not exceed the aggregate of the Work Package
                                         Budgets for the Work Packages comprising the Project.

 

		18.5	Exclusions.
                                         Except as provided by Clause 18.6, neither Party shall be liable to the other Party for
                                         indirect loss of profits, incidental or consequential damages, whether in contract, warranty,
                                         negligence, tort, strict liability or otherwise, arising out of any breach of or failure
                                         to perform any of the provisions of this Agreement.

 

		18.6	Exclusions
                                         from liability cap. Nothing in this Agreement shall limit the liability of either
                                         Party for:

 

		18.6.1.	personal
                                         injury or death arising out of that Party’s negligence or willful misconduct; or

 

		18.6.2.	fraud
                                         or fraudulent misrepresentation or willful misconduct.

 

		18.7	Third
                                         Party Claims. The Partner agrees to indemnify CEPI and hold CEPI harmless from and
                                         against any and all claims, damages, and liabilities asserted by Third Parties (including
                                         claims for negligence) which arise directly or indirectly from a material breach of Partner
                                         or its grossly negligent conduct under this Agreement except to the extent such claims
                                         are in connection with the negligence or willful conduct by CEPI. And CEPI agrees to
                                         indemnify Partner and hold Partner harmless from and against any and all claims, damages,
                                         and liabilities asserted by Third Parties (including claims for negligence) which arise
                                         directly or indirectly from a material breach of CEPI or its grossly negligent conduct
                                         under this Agreement except to the extent such claims are in connection with the negligence
                                         or willful conduct by the Partner.

 

    36

     

    

 

		18.8	Conduct
                                         of Third Party claims. The Parties shall use reasonable endeavors to avoid, dispute,
                                         resist, appeal, compromise or defend any Third Party claims brought against it and to
                                         minimize its losses, claims, liabilities, costs, charges and expenses and give the other
                                         Party prompt written notice of any Third Party claim for which it requires indemnification
                                         under this Clause 18 together with copies of all relevant papers and official documents.
                                         The Parties shall agree how to respond to and handle the Third Party claim in an efficient
                                         manner. The Parties agree not to take any material action in respect of any Third Party
                                         claim without the consent of the other Party (such consent not to be unreasonably withheld,
                                         conditioned or delayed), including settlement of any such Third Party claim.

 

		18.9	Partner
                                         insurance obligations. The Partner will obtain and continuously maintain the insurance
                                         on a claims arising basis with an insurance company of a credit rating of A or better
                                         as set out below and CEPI will bear such costs to the extent modifications of the insurance
                                         coverage are triggered by the collaboration hereunder:

 

		18.9.1.	During
                                         the period covered by the IPDP. clinical trials insurance as follows:

 

		(i)	the
                                         Partner (to the extent the Partner is the sponsor of a clinical trial of Project Vaccine)
                                         shall obtain and shall ensure that any Sub-Contractor that is the sponsor of a clinical
                                         trial shall obtain, clinical trial insurance on a claims arising basis of at least €
                                         [*****] per patient and € [*****] for all insured events from one study per claim
                                         including non-negligence cover, such insurance to be effective from the commencement
                                         date of the clinical trial until at least [*****] after the completion of the clinical
                                         trial or such longer period as is required by the relevant ethical committee or an applicable
                                         statutory period of limitation;

 

		(ii)	During
                                         the Project Term and for [*****] afterwards, general commercial liability insurance including
                                         contractual liability of at least € [*****] per insured event for personal injury
                                         and property damage;

 

		(iii)	The
                                         Partner shall comply with the terms of these insurance policies for the term and for
                                         at least the duration of any applicable statutory period of limitation afterwards;

 

		(iv)	The
                                         Parties acknowledge that as at the Effective Date the World Health Organization (“WHO”)
                                         is considering an insurance mechanism which would provide insurance cover for the suppliers
                                         of investigational products for use in the case of a “Public Health Emergency of
                                         International Concern” declared by WHO. The Parties agree that when this mechanism
                                         is in place the Parties will discuss in good faith the impact of such arrangement on
                                         the Parties’ obligations under this Agreement and how it will apply to the supply
                                         of Product in an Outbreak or Outbreak risk.

 

18.10       CEPI
insurance obligations. On exercise of the Public Health License, CEPI will procure that:

 

		18.10.1.	equivalent
                                         insurance protection for the Partner to that specified at Clause 18.9 is in place in
                                         respect of the Development and Manufacturing of Project Vaccine for use in the Field
                                         in the Affected Territories conducted by or on behalf of CEPI;

 

		18.10.2.	procure that the
                                         insurer notes Partner’s interest on each such insurance policy;

 

    37

     

    

 

		18.10.3.	provide
                                         Partner with a copy of each such insurance policy and certificate and annually on renewal;
                                         notify Partner of any claims made under these policies relating to Project Vaccine for
                                         use in the Field in the Affected Territory for the Project Term and for at least the
                                         duration of any applicable statutory period of limitation afterwards; and

 

		18.10.4.	procure
                                         compliance with the terms of these insurance policies for the Project Term and for at
                                         least the duration of any applicable statutory period of limitation afterwards.

 

19.       TERM,
TERMINATION AND EFFECTS OF TERMINATION

 

		19.1	Term.
                                         This Agreement shall commence on the Effective Date and, unless otherwise agreed between
                                         the Parties in a Work Package or Additional Work Package, shall continue in full force
                                         and effect for a term of three (3) years from the Effective Date and then expires or
                                         earlier if terminated pursuant to this Clause 19 (the “Project Term”).

 

		19.2	Termination.
                                         Either Party (the “Terminating Party”) may terminate at any time by
                                         giving written notice of termination to other Party (the “Defaulting Party”)
                                         where:

 

		19.2.1.	the
                                         Defaulting Party commits a breach of a material obligation set out in this Agreement
                                         which is not capable of remedy or, where capable of remedy, has not been remedied within
                                         [*****] of the receipt by it of a notice from the
                                         Terminating Party identifying the breach and requiring its remedy or as otherwise agreed
                                         in writing by the Parties; or

 

		19.2.2.	the
                                         Defaulting Party is unable or admits inability to pay its debts as they fall due, suspends
                                         making payments on any of its debts or, by reason of actual or anticipated financial
                                         difficulties commences negotiations with one or more of its creditors with a view to
                                         rescheduling any of its indebtedness, or has filed in any court or agency pursuant to
                                         any statute or regulation of any state or country, a petition in bankruptcy or insolvency
                                         or for reorganization or for an arrangement or for the appointment of a receiver or trustee
                                         of the Defaulting Party or of its assets, or if the Defaulting Party proposes a written
                                         agreement or composition or extension of its debts, or if the Defaulting Party is served
                                         with an involuntary petition against it, filed in any insolvency proceeding, and such
                                         petition is not dismissed within [*****] after the filing thereof, or if the Defaulting Party has proposed or is a party
                                         to any dissolution or liquidation (other than where the Defaulting Party is a creditor
                                         claiming repayment in such dissolution or liquidation), or if the Defaulting Party makes
                                         an assignment for the benefit of its creditors.

 

		19.3	Additional
                                         CEPI termination rights. In addition to the termination rights above, CEPI shall
                                         be entitled to terminate this Agreement unilaterally with immediate effect by providing
                                         written notice to the Partner in the following circumstances:

 

		19.3.1.	the
                                         Partner takes any action incompatible with or which would have an adverse effect (or
                                         by omitting to take any action has or would have a similar adverse effect) on CEPI’s
                                         mission or reputation or the Partner’s ability to comply with its obligations under
                                         the Agreement including where the Partner is unable to achieve the next Milestone Criteria
                                         or Stage Gate Criteria by the relevant Milestone Date Stage Gate Date or by the expiry
                                         of any cure period agreed between the Parties in writing, or where the Partner fails
                                         to take corrective action within any period of time granted to the Partner by CEPI; or

 

    38

     

    

 

		19.3.2.	the
                                         Parties are unable to agree a suitable replacement Project Lead within [*****] of the
                                         notification referred to in Clause 5.2;

 

		19.3.3.	the
                                         JMAG does not approve the IPDP or Marketing Activities Plan;

 

		19.3.4.	on
                                         a change of Control of the Partner without CEPI’s prior written agreement, unless
                                         the Third Party in Control of the Partner: (i) has confirmed in writing to CEPI that
                                         it has sufficient capital, expertise and commitment, either itself or through the Partner,
                                         to carry on the Partner’s business as a going concern and (ii) to meet the Partner’s
                                         obligations under this Agreement to at least at the same level as the Partner prior to
                                         such change of Control; and

 

		19.3.5.	where
                                         there are material Safety Issues and/or quality issues in relation to one or more Project
                                         Vaccines or use of the Platform that will seriously impact the long-term viability of
                                         one or more of Project Vaccines or the Platform. In such circumstances, the Partner shall
                                         immediately cease using the Platform and cease Developing and Manufacturing a Project
                                         Vaccines directly or indirectly for use in the Field except to the extent required to
                                         identify the cause of the Safety Issue and immediately commence a Product recall.

 

		19.4	Dispute.
                                         Where there is a dispute between the Parties in relation to this Clause, the matter
                                         shall be resolved in accordance with the dispute resolution procedure set out below,
                                         and the Parties shall comply with the provisions of this Agreement unless and until the
                                         dispute is settled.

 

	20.	EFFECTS OF TERMINATION

 

		20.1	CEPI’s
                                         right to use the Background Technology and Project Technology, where the Partner is the
                                         Defaulting Party or where termination is pursuant to Clause 19.3. With effect from
                                         the expiry of the Project Term (“Termination Date”), CEPI’s
                                         licenses hereunder to the Background Technology and Project Technology in the Field and
                                         in the Affected Territories, as well as the Commercial Benefits sharing shall survive
                                         to:

 

		20.1.1.	Develop
                                         and use the Platform for use in the Field via Trusted Manufacturers; Manufacture Product
                                         for use in the Field via Trusted Manufacturers;

 

		20.1.2.	compare
                                         and contrast the relative advantages and disadvantages of the Platform and alternative
                                         platforms for use in the Field; and

 

		20.1.3.	compare
                                         and contrast the relative advantages and disadvantages of Project Vaccines for use in
                                         the Field against the advantages and disadvantages of alternative equivalent products
                                         for use in the Field.

 

		20.2	Provisions of Clause
                                         8. With effect from the Termination Date, the provisions of Clause 8 will cease to
                                         have effect.

 

    39

     

    

 

		20.3	Partner
                                         supplies of Product. The Partner shall have the right to exhaust supplies of Project
                                         Vaccines then in inventory in performance of its obligations under any agreement for
                                         supply with a public sector agency or if no such agreement exists at the Termination
                                         Date, immediately transfer ownership of the same to CEPI at no cost and inform any Third
                                         Party GMP storage facility of the same forthwith.

 

		20.4	Transfer
                                         of applications to and approvals from Regulatory Authorities. The Partner shall use
                                         all reasonable endeavors to transfer to CEPI (or its nominee) promptly and at the Partner’s
                                         cost, all submissions to Regulatory Authorities, Regulatory Filings, Platform Confirmations
                                         and Master Files related thereto.

 

		20.5	Materials.
                                         To the extent not already provided, the Partner shall provide to CEPI (or its nominee)
                                         at the Partner’s cost all Materials, Data, Documents and Know-how required to exercise
                                         CEPI’s rights under this Clause within [*****] of CEPI requesting such Materials.

 

		20.6	Contracts.
                                         Subject to applicable confidentiality obligations, the Partner shall provide CEPI
                                         with copies of all Sub-Contracts which relate to the Development of the Platform for
                                         use in the Field, the Development of Project Vaccine and the Manufacturing of Product
                                         in the Field and access to which is required for Third Party Manufacturers within [*****]
                                         of the Termination Date. Provided that the termination of this Agreement was not caused
                                         directly or indirectly by the Sub-Contractor and that Sub-Contractor is not then in breach,
                                         the Partner shall use all Reasonable Efforts, at CEPI’s reasonable request, to
                                         facilitate the conclusion of a direct contractual relationship between the Sub-Contractor
                                         and CEPI or Trusted Manufacturer, to the extent required for CEPI or its nominee.

 

		20.7	Unspent
                                         CEPI funding. Where termination occurs prior to the end of a Work Package and affects
                                         such Work Package, CEPI shall not be required to make any further payments of CEPI funding
                                         to the Partner under this Agreement or any Work Package Statement other than to reimburse
                                         the Partner for any non-cancellable expenses incurred in accordance with the Work Package
                                         Budget prior to the Termination Date and the Partner shall return any Work Package Budget
                                         received from CEPI under the Work Package Budget under this Agreement which is unspent
                                         at the date of termination (after deduction of costs incurred and non-cancellable commitments
                                         incurred prior to the date of termination) within [*****] after the date of the notice
                                         of termination.

 

20.8       Repayment
of CEPI funding by Partner.

 

		20.8.1.	Where
                                         termination is due to any material financial irregularity or as a consequence of fraudulent
                                         or illegal activity by the Partner. Partner shall repay to CEPI (to the extent it
                                         is able to without triggering its insolvency, breach of another philanthropic donor’s
                                         grant or contract with Partner) the amount of funds directly related to such financial
                                         irregularity or fraudulent or illegal activity within [*****] of the notice of termination.
                                         The Partner shall use its Reasonable Efforts to insert and enforce similar reimbursement
                                         provisions in its agreements with Sub-Contractors.

 

		20.8.2.	Where
                                         termination is for failure to achieve one or more Milestones by the applicable Milestone
                                         Date and such failure constitutes a material breach by Partner of its obligations
                                         under this Agreement, and that breach has not been remedied, Partner will return a sum
                                         equal to the CEPI funding that CEPI has paid to it for the then ongoing Work Package
                                         or Additional Work Package, as at the date of notice of termination (less the unspent
                                         funds, which are to be handled in accordance with Clause and also less funds which have
                                         been spent or reasonably committed to third parties) to CEPI within [*****] of the notice
                                         of termination.

 

    40

     

    

 

		20.9	Use
                                         of Platform and Project Vaccines by Partner. Consistent with other obligations in
                                         this Agreement, the Partner may at its discretion continue to use the Project Technology
                                         for any purpose.

 

		20.10	Effects
                                         of Termination where CEPI is the Defaulting Party. Where termination occurs prior
                                         to the end of the Project Term, CEPI shall make all payments agreed to be made for any
                                         Work Package in regard to expenditures that have been commited by the Partner.

 

		20.11	Project
                                         Technology. Subject to Clauses 13 and 20, the Partner may at its discretion use the
                                         Project Technology for any purpose.

 

20.12       Survival
of Clauses.

 

		20.12.1.	Termination
                                         and expiry of this Agreement howsoever arising shall be without prejudice to the rights
                                         and duties of either Party accrued prior to termination. The Clauses in this Agreement
                                         which expressly or impliedly have effect after or notwithstanding termination (including
                                         Clauses 1, 3.12, 3.13, 3.15, 3.16, 4.6, 8 (except where Clause 20.2 applies), 11 to 17
                                         inclusive, 18.4, 18.5, 18.6, 18.7, 18.8, 20 to 22 inclusive shall continue to
                                         be enforceable notwithstanding termination. Unless otherwise agreed, the Parties shall
                                         not enter into any further Work Package Statements after the date of termination.

 

		20.12.2.	If
                                         the Partner terminates this Agreement during or after the Project Term for cause, owing
                                         to a material and unrepaired breach by CEPI, the licenses granted under this Agreement
                                         shall terminate and the survival under this Clause 20.11 shall not apply.

 

		20.13	Clinical
                                         Trial Wind-down. Where at the date of termination there is an on-going clinical trial,
                                         unless agreed otherwise by the Parties in writing, the Partner shall procure that no
                                         further trial subjects are entered into the clinical trial, and the JMAG and TSC shall
                                         work together to plan for the appropriate and ethical completion or wind-down of Development
                                         activities in an orderly fashion, with due regard for patient safety and the rights of
                                         any subjects that are participants in clinical trial and in consultation with any relevant
                                         ethical committee.

 

21.       GENERAL

 

21.1       Conflicts.
If there is any conflict between the provisions of:

 

		21.1.1.	the
                                         main body of this Agreement and the CEPI Policies, then the provisions of this Agreement
                                         shall prevail;

 

		21.1.2.	the
                                         main body of this Agreement and any Work Package Statement, then the provisions of the
                                         Work Package Statement shall prevail; and
	 	 	 

		21.1.3.	any Work Package
                                         Statement and the CEPI Policies, then the provisions of the Work Package Statement shall
                                         prevail,

 

    41

     

    

 

		21.2	Waiver.
                                         Neither Party shall be deemed to have waived any of its rights or remedies under this
                                         Agreement unless the waiver is expressly made in writing and signed by a duly authorized
                                         representative of that Party. In particular, no delay or failure of either Party in exercising
                                         or enforcing any of its rights or remedies under this Agreement shall operate as a waiver
                                         of those rights or remedies nor shall any single or partial exercise or enforcement of
                                         any right or remedy by a Party preclude or impair any other exercise or enforcement of
                                         that right or remedy by that Party.

 

		21.3	Entire
                                         Agreement. This Agreement, including its Schedules attached hereto, together with
                                         the Work Package Statements and the CEPI Policies constitutes the entire agreement and
                                         understanding between the Parties relating to the subject matter hereof and together
                                         they supersede and replace all prior drafts, previous understandings, arrangements, representations
                                         or agreements, whether in writing or oral, between the Parties relating to the subject
                                         matter of this Agreement. Each Work Package Statement shall be part of this Agreement
                                         and shall not form a separate contract to it.

 

		21.4	Variation.
                                         No variation, amendment, modification or supplement to this Agreement shall be valid
                                         unless and until it is made in writing and signed by a duly authorized representative
                                         of each Party. Once a Work Package Statement has been signed by both Parties, no amendment
                                         shall be made to it except if the amendment is in writing, has been approved by the JMAG
                                         and has been signed by a duly authorized representative of each Party.

 

		21.5	Assignment.
                                         Neither Party shall, without the prior written consent of the other Party assign, transfer,
                                         convey or declare a trust over this Agreement or make any other disposition (whether
                                         in whole or in part) of any of its rights and obligations hereunder to any Third Party,
                                         including by novation, except that CEPI may transfer its rights and obligations to Wellcome,
                                         Gates or an organization of equivalent charitable mission, if CEPI considers (in good
                                         faith) that CEPI will not be in a position to fulfil its obligations or exercise its
                                         rights in the future. Partner shall have a right to assign this Agreement to an Affiliate
                                         or a Third Party which acquires all or substantially all of the assets related to the
                                         collaboration under this Agreement. In the event that the Partner is considering any
                                         of the actions referred to above, Partner shall promptly notify CEPI and CEPI will have
                                         the right to conduct such due diligence as CEPI, in its sole discretion, deems appropriate
                                         prior to such action completing and prior to CEPI notifying the Partner of its decision.

 

		21.6	Severance
                                         of Terms. If the whole or any part of this Agreement is or becomes or is declared
                                         illegal, invalid or unenforceable in any jurisdiction for any reason (including both
                                         by reason of the provisions of any legislation and also by reason of any court or competent
                                         authority which either has jurisdiction over this Agreement or has jurisdiction over
                                         either Party): in the case of the illegality, invalidity or un-enforceability of the
                                         whole of this Agreement it shall terminate only in relation to the jurisdiction in question;
                                         and in the case of the illegality, invalidity or un-enforceability of part of this Agreement
                                         that part shall be severed from this Agreement in the jurisdiction in question and that
                                         illegality, invalidity or un-enforceability shall not in any way whatsoever prejudice
                                         or affect the remaining parts of this Agreement, which shall continue in full force and
                                         effect. If in the reasonable opinion of any Party any severance under this Clause materially
                                         affects the commercial basis of this Agreement, the Parties shall discuss, in good faith,
                                         ways to eliminate the material effect.

 

    42

     

    

 

		21.7	Costs.
                                         Each Party shall bear its own legal costs, legal fees and other expenses incurred in
                                         the preparation, negotiation and execution of this Agreement and any Work Package Statements.

 

		21.8	Further
                                         Assurances. Each Party shall perform such acts and execute such documents as may
                                         be reasonably required for securing to or vesting in the other Party the rights agreed
                                         to be granted to it under or pursuant to this Agreement.

 

		21.9	Notices.
                                         Any notice to be given pursuant to this Agreement shall be in writing in the English
                                         language and shall be delivered by overnight courier, by registered, recorded delivery
                                         or certified mail (postage prepaid) to the address of the recipient Party set out below
                                         or such other address as a Party may from time to time designate by written notice to
                                         the other Party:

 

Address of
the Partner:

 

Partner

 

CureVac AG

 

Paul-Ehrlich-Strasse
15

 

72076 Tübingen

 

Germany

 

For the attention
of: CEO

 

With a copy
to: Director Legal

 

 

 

CEPI

 

Gibbs Building,
215 Euston Road

 

Bloomsbury,
London

 

NW1 2BE

 

United Kingdom

 

For the attention
of:   [*****]   General Counsel

 

With a copy
to:   [*****]   Director of Vaccine Development

 

Any
notice given pursuant to this Clause shall be deemed to have been received on the day of receipt, provided receipt occurs on a
Business Day of the recipient Party or otherwise on the next following Business Day of the recipient. The Parties agree that email
and fax are not valid methods of giving notice under this Agreement except that notification of Safety Issues as required by Clause
7.6 should be communicated to the relevant JMAG Members by email (with receipt acknowledgement) in the interests of urgency as
well as sent in writing in accordance with this Clause 21.9.

 

    43

     

    

 

		21.10	Partnership.
                                         Nothing in this Agreement shall be taken to constitute a partnership between the Parties.
                                         Except as specifically provided in this Agreement, neither Party shall by reason of this
                                         Agreement be empowered to act as agent for the other Party nor to pledge the credit of
                                         the other Party nor shall either Party be held liable for or incur liability in respect
                                         of the acts or defaults of the other Party to this Agreement.

 

		21.11	Counterparts.
                                         This Agreement may be executed in any number of counterparts, including electronic counterparts,
                                         and by the Parties on separate counterparts, but shall not be effective until each Party
                                         has executed at least one counterpart. Each counterpart shall constitute an original
                                         of this Agreement, but all the counterparts shall together constitute one and the same
                                         instrument.

 

		21.12	Rights
                                         of Third Parties. Except for Wellcome and Gates, a person who is not a Party has
                                         no right under the Contracts (Rights of Third Parties) Act 1999 to enforce or to enjoy
                                         the benefit of any term of this Agreement.

 

		21.13	Force
                                         Majeure. Neither Party shall be deemed to have defaulted under or to be in breach
                                         of this Agreement for failure or delay in fulfilling material obligations when such failure
                                         or delay is directly caused by an event, including but not limited to war, acts of war,
                                         insurrections, acts of terrorism, acts of God (excluding the outbreak of disease) or
                                         acts, omissions or delays in acting or failure to act by any of CEPI’s funders.
                                         Should any of the aforementioned occur, each Party shall inform the other in writing
                                         of such event, act, omission or delay and the Parties will discuss the situation, and
                                         acting in good faith, agree on the appropriate course of action under the circumstances.
                                         In the event of issues regarding CEPI funders, then those courses of action may include,
                                         without limitation, revised payment schedules or assignment pursuant to Clause 21.5 above.

 

22.       DISPUTE
RESOLUTION, GOVERNING LAW AND JURISDICTION

 

		22.1	Escalation
                                         process. Any question, difference or dispute which may arise concerning the construction,
                                         meaning or effect of this Agreement, or concerning the rights or liabilities of the Parties
                                         hereunder, or any other matter arising out of or in connection with this Agreement shall
                                         first be submitted to the Chief Executive Officer of CEPI and the Chief Executive Officer
                                         of the Partner (the “Senior Officers”) for resolution (each of whom
                                         may call on others to advise them as they see fit) unless this Agreement expressly provides
                                         otherwise. The Senior Officers shall discuss the matter in good faith and in a timely
                                         manner and endeavor to reach a mutually agreeable solution. If the Parties are unable
                                         to resolve such dispute through such negotiations within [*****]
                                         of such dispute being escalated to the Senior Officers, then in respect of any
                                         dispute, controversy or claim other than those that concern: the validity or infringement
                                         of Technology; anti-trust, anti-monopoly or competition law or regulation; and/or breach
                                         or threatened breach of Clauses 14, 15 and 17, the Parties irrevocably submit to arbitration
                                         in accordance with Clause 22.2. In respect of disputes relating to the validity or infringement
                                         of Technology; anti-trust, anti-monopoly or competition law or regulation; and/or breach
                                         or threatened breach of Clauses 14, 15 and 17, the Parties irrevocably submit to the
                                         exclusive jurisdiction of the Courts of England and Wales.

 

		22.2	Arbitration.
                                         Any disputes to be resolved by binding arbitration shall be referred to and finally resolved
                                         by arbitration under the Rules of the London Court of International Arbitration, which
                                         Rules are deemed to be incorporated by reference into this Clause. The number of arbitrators
                                         shall be one in event of a dispute in connection with an Outbreak. Otherwise the number
                                         of arbitrators shall be three. The seat, or legal place, of arbitration shall be London,
                                         England. The language to be used in the arbitral proceedings shall be English.

 

		22.3	Governing Law. This
                                         Agreement (and any dispute, controversy, proceedings or claim of whatever nature arising
                                         out of this Agreement or its formation) shall be governed by and construed in accordance
                                         with the laws of England and Wales, except for questions regarding the validity of patents,
                                         which shall be resolved in the courts having jurisdiction over the patents in question
                                         and in accordance with the laws applicable to such patents.

 

    44

     

    

 

 

IN
WITNESS whereof the Parties through their duly authorized representatives have
executed this Agreement.

 

Signed for and on behalf
of CUREVAC AG by its duly authorized signatories:

 

	Signature:	/s/ Janiez
    Menichezla	 
	 	 
	NAME: 	JANIEZ MENICHEZLA	 
	 	 
	TITLE: 	CEO	 
	 	 
	Date:	2/14/2019	 
	 	 
	Signature:	/s/ Franz-Werner Haas	 
	 	 	 
	NAME:	Franz-Werner Haas	 
	 	 	 
	TITLE:	Chief Operating Officer	 
	 	 
	Date: 	February 14,2019	 

 

Signed for and on behalf
of COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS by its duly authorized signatory:

 

Signature:

 

NAME:

 

TITLE:

 

Date:

 

    45

     

    

 

IN
WITNESS whereof the Parties through their duly authorized representatives have
executed this Agreement.

 

Signed for and on behalf
of CUREVAC AG by its duly authorized signatory:

 

Signature:

 

NAME:

 

TITLE:

 

Date:

 

Signature:

 

NAME:

 

TITLE:

 

Date:

 

Signed for and on behalf
of COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS by its duly authorized signatory:

 

	Signature:	/s/
    Richard Hatchett	 
	 	 
	NAME:	RICHARD HATCHETT	 
	 	 
	TITLE:	CEO	 
	 	 
	Date:	15 February 2019	 

 

    46

     

    

 

 

SCHEDULE
1

 

TEMPLATE
FOR WORK PACKAGE STATEMENTS

 

    47

     

    

 

Work
Package Statement

[Description of Work Package]

 

Made
on                                                                                         (the
 “Effective Date”)

 

Between:

		1.	COALITION
                                         FOR EPIDEMIC PREPAREDNESS INNOVATIONS,
                                         a not-for-profit international association existing under Norwegian law with address
                                         at Marcus Thranesgate 2, PO box 123 Torshov, N-0412 Oslo Norway (“CEPI”);
                                         and

 

		2.	XXXXXXXXXXXX,  a private company existing under XXXXX law with address
                                                                                                             at XXXXXXXXXXXXXXXXXXXXXXXXX. (“XXXXXXX”, or the
                                                                                                             “Partner”).

 

INTRODUCTION

 

This document is a Work
Package Statement pursuant to the Framework Partnering Agreement dated [             ] and
entered into by the Parties (the “Partnering Agreement”) and outlines the tasks and actions which take place
during the execution of [description of disease and work package].

 

NOW IT IS AGREED THAT:

 

		1.	Defined terms in this
                                         Work Package Statement shall have the meaning given to them in the Partnering Agreement
                                         unless otherwise stated.

 

2.       The
Partner shall:

 

		a.	perform all activities
                                         set out in Schedule 1 and provide the Partner Contribution, if any, set out in Schedule
                                         2 to deliver the Deliverables set out in Schedule 3, Part 1;

 

		b.	use Reasonable Efforts
                                         to achieve the Milestones Criteria set out in Schedule 3, Part 2 by the applicable Milestone
                                         Date;

 

		c.	ensure that all Contractor
                                         Results are produced on behalf of the Partner, as set out in Schedule 3, Part 3; and

 

		d.	use Reasonable Efforts
                                         to achieve the Stage Gates set out in Schedule 4 by the applicable Stage Gate Date.

 

		3.	CEPI shall make payments
                                         to the Partner up to a maximum of the Work Package Budget set out in Schedule 5 in accordance
                                         with Clauses 3.7 – 3.12 of the Partnering Agreement.

 

		4.	The terms and provisions
                                         of the Partnering Agreement are incorporated by reference to this Work Package Statement
                                         and all rights and obligations arising under this Work Package Statement shall be governed
                                         by and construed in accordance with the terms of the Partnering Agreement.

 

    48

     

    

 

IN WITNESS whereof the
Parties through their duly authorised representatives have executed this Agreement.

 

Signed for and on behalf
of COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS by its duly authorised signatory:

 

Signature:

 

Name:

 

Title:

 

Date:

 

Signed for and on behalf
of XXXXXXXXXXXXX by its duly authorised signatory:

 

Signature:

 

Name:

 

Title:

 

Date:

 

    49

     

    

 

SCHEDULE 1 –
ACTIVITIES

 

    50

     

    

 

SCHEDULE 2 –
PARTNER CONTRIBUTION

 

[To be completed,
or deliberately left blank]

 

SCHEDULE 3 –
DELIVERABLES, MILESTONES & CONTRACTOR RESULTS

 

PART 1

 

DELIVERABLES LIST

The Deliverables for
this work package are listed below:

 

	Deliverable	Description	Date
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

PART
2

 

MILESTONE LIST

The specific Milestones
for this work package are listed below:

 

	Milestone	Milestone
    Criteria	Milestone
	Number	Date
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

 

PART
3

 

CONTRACTOR RESULTS
LIST

 

For each Contractor /
Subcontractor please provide the following information:

 

Contractor / Subcontractor
1

 

    51

     

    

 

Name of Contractor /
Subcontractor:

Registered Address:

Location of Incorporation:

Company Number (where
relevant):

Overview of the role
they shall perform:

 

	Contractor
    Result	Description	Date
	 	 	 

 

Contractor / Subcontractor
2

 

Name of Contractor /
Subcontractor:

Registered Address:

Location of Incorporation:

Company Number (where
relevant):

Overview of the role
they shall perform:

 

	Contractor
    Result	Description	Date
	 	 	 

 

SCHEDULE 4 –
STAGE GATES

 

	Stage
    Gate Criteria	Stage
    Gate Date
	 	 

 

SCHEDULE 5 –
WORK PACKAGE BUDGET

 

A summary of the Work
Package Budget by cost category is set out below. A detailed budget is attached as Schedule 5.1 to this Work Package Statement.

 

	WP
    [description]	Budgeted	Comments
	 	Total	 
	Personnel	 	 
	Travel	 	 
	Consultants	 	 
	Equipment	 	 
	Other
    Direct Costs	 	 
	Sub-awards	 	 
	Total
    Direct Cost	 	 
	Indirect
                                         Cost Rate

        on
        Primary

        awardee’s
        Portion
	 	 
	Primary
                                         awardee’s

        Indirect
        Cost Rate

        on
        Sub-award

        Portion
	 	 
	WP
                                        [description]

        Total
        Budget
	 	 

 

    52

     

    

 

SCHEDULE 6 –
PAYMENT SCHEDULE

 

	Quarterly
                                         Report -

        due
        each project quarter

        within
        20 Business Days of

        the
        periods ending:
	Financial
                                         Summary &

        Reporting
        Form - due each

        project
        quarter within 20

        Business
        Days of the periods

        ending:
	Payment
                                         requests - due

        every
        6 months with the

        Financial
        Summary &

        Reporting
        Forms for the

        periods
        ending:

	31
    March	31
    March	30
    June
	30
    June	30
    June	31
    December
	30
    September	30
    September	 
	31
    December	31
    December	 

 

    53

     

    

 

 

SCHEDULE
2

 

PARTNER
CONTRIBUTION

 

[*****]

 

    54

     

    

 

SCHEDULE
3

 

BACKGROUND
TECHNOLOGY 

 

[*****]

 

    55

     

    

 

SCHEDULE
4

 

CEPI
FUNDING AND PROJECT BUDGET

 

[*****]

 

    56

     

    

 

SCHEDULE
5

 

WORK
PACKAGE STATEMENTS

 

[*****]

 

    57

     

    

 

Schedule
5

 

Work
Package Statements

[*****]

 

    58

     

    

 

Appendix F

 

[*****]

 

    59

     

    

 

Schedule 6

 

IPDP 

 [*****]

 

    60

     

    

 

SCHEDULE 7

 

COST OF GOODS

SOLD FORMULA

 

[*****]

 

    61

     

    

 

SCHEDULE 8

 

TEMPLATE
FINANCIAL SUMMARY AND REPORTING FORM 

 

This
file consists of seven worksheets (in addition to this one):

 

		1.	Cover
                                         Letter, Quarterly should be completed,
                                         signed by an authorised representative for the awardee, and submitted to CEPI (in pdf)
                                         together with the quarterly financial report.

 

		2.	Financial
                                         Summary. In order to follow the disbursement
                                         cycles, the columns are divided into biannual groups (two quarters), and the rows are
                                         grouped by the work packages.

 

		·	First,
                                         choose the relevant year and quarter by clicking the + on top of the sheet

		·	Second,
                                         choose the relevant work package(s) by clicking the + on the left-hand side

 

Once
every six months the projected expenditure for the upcoming period should be completed. Please note that the projected expenditure
cannot exceed six months.

Please
fill in the actual expenditure for the relevant quarter and the relevant sub-work package. Please include only expenditure that
has actually been incurred and reimbursed during the quarterly period.

 

		3.	Notes.
                                         Please explain expenditure that deviates notably from the projections.

 

		4.	Financial
                                         Narrative. Please answer the narrative
                                         questions. We recommend that a transcript of your complete transactions for the current
                                         quarterly reporting period is provided in a separate attachment.

 

		5.	Work-Package
                                         Statement. For completion by CEPI only
                                         - visible for Awardee’s reference.

 

		6.	Asset
                                         register should be completed upon purchase
                                         of new equipment/capital expenditure.

 

		7.	Biannual
                                         Payment Request should be completed,
                                         signed by an authorised representative for the awardee, and submitted to CEPI (in pdf)
                                         when requesting payment for the upcoming biannual period.

 

The
file is protected. It is only possible to insert data into yellow and green cells:

 

Enter
information into light yellow cells

Enter
actual expenditures into green cells

 

If
you need more space to write in the yellow cells, drag the boundary to expand it:

 

 

 

    62

     

    

 

	 	 	 
	To
    be completed by CEPI	 
	Import
    date	 
	 	 	 	 
	Cost
    center	 	 
	 	 	Coalition
    for Epidemic Preparedness Innovations, CEPI
	Import
    text	 	Marcus
    Thranes gate 2
	 	 	0473
    OSLO
	 	 	Norway
	 	 	Registration
    number: 917687811
	 	 	 
	Awardee
    name	 	 
	 	 	 
	Address	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Reg.no.	 	 
	 	 	 
	Subject:
    	Quarterly
    Financial Report	 
	 	 	 
	Your
    reference	 	 
	 	 	 
	CEPI’s
    reference 	INCU1901	 
	 	 	 
	Financial
    report number	 	 
	 	 	 
	Start
    date, financial reporting period	 	 
	 	 	 
	End
    date, financial reporting period	 	 
	 	 	 
	Funding
    from other donor	 	If
    Yes, please state donor name(s) and amount(s) for the
	 	 	current
    reporting period:
	 	 	 
	 	 	 
	Main
    currency for Awardee	 	If
    Other, please state currency and exchange rate
	 	 	against
    the USD used for the current reporting period:
	 	 	 
	 	 	 
	Currency
    Sub-awardees	 	Please
    list all sub-awardees that use other currencies than
	 	 	USD,
    and state their exchange rate against the
	 	USD
    used for the current reporting period:
	 	 
	 	 
	Indirect
    cost rate on primary Awardee’s portion	 
	Primary
    awardee’s indirect cost rate on Sub-award portion	 
	 	 
	I
    hereby declare that to the best of my knowledge all information provided in this financial report is full, reliable and true.
	 	 
	 	 
	Place
    and date	Signature
    authorised representative
	 	 
	 	 
	 	Printed
    name and title

 

    63

     

    

 

 

	Year
    1, Q1 & Q2	 	Year
    1, Q3 & Q4	 	Year
    2, Q1 & Q2	 
	 	 	Projected

    Q1&Q2

    Expenditure	 	 	Q1
    Actual

    Expenditure	 	 	Q2
    Actual

    Expenditure	 	 	Variance,
$	 	 	Variance,

    %	 	Note

    no.	 	Projected

    Q3&Q4

    Expenditure	 	 	Q3
    Actual

    Expenditure	 	 	Q4
    Actual

    Expenditure	 	 	Variance,
$	 	 	Variance,

    %	 	Note

    no.	 	Projected

    Q1&Q2

    Expenditure	 	 	Q1
    Actual

    Expenditure	 	 	Q2
    Actual

    Expenditure	 	 	Variance,
$	 	 	Variance,

    %	 	 	Note

    no.	 
	Total, Completed work
    packages	 	$	              -	 	 	$	              -	 	 	$	              -	 	 	 	 	 	 	 	 	 	 	 	$	              -	 	 	$	              -	 	 	$	              -	 	 	 	 	 	 	 	 	 	 	 	$	              -	 	 	$	              -	 	 	$	              -	 	 	 	 	 	 	 	 	 	 	 	 
	Work package 1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total
    WP 1	 	$	-	 	 	$	-	 	 	$	-	 	 	$	          -	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	          -	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	          -	 	 	 	 	 	 	 	 
	WP1.1 Research
    batch Ag #1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	           0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	           0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	           0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 1.1	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	WP1.2
    Preclinical POC Ag #1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 1.2	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	WP1.3
    Regulatory Ag #1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 1.3	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Work
    package 2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total WP 2	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 
	WP2.1
    Research batch Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 2.1	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	WP2.2
    Preclinical POC Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 2.2	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	WP2.3
    Development & GMP Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 2.3	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	WP2.4
    Regulatory Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 2.4	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 

 

 

    64

     

     

	Year
    2, Q3 & Q4	 	 	Year
    3, Q1 & Q2	 	 	Year
    3, Q3 & Q4	 	 	 	 	 	 	 	 	 	 
	Projected
    Q3&Q4	 	 	Q3 Actual	 	 	Q4 Actual	 	 	Variance,	 	 	Variance,	 	 	Note	 	 	Projected
    Q1&Q2	 	 	Q1 Actual	 	 	Q2 Actual	 	 	Variance,	 	 	Variance,	 	 	Note	 	 	Projected
    Q3&Q4	 	 	Q3 Actual	 	 	Q4 Actual	 	 	Variance,	 	 	Variance,	 	 	Note	 	 	Budget	 	 	Total
    Cumulative	 	 	Available	 
	Expenditure	 	 	Expenditure	 	 	Expenditure	 	 	$	 	 	%	 	 	no.	 	 	Expenditure	 	 	Expenditure	 	 	Expenditure	 	 	$	 	 	%	 	 	no.	 	 	Expenditure	 	 	Expenditure	 	 	Expenditure	 	 	$	 	 	%	 	 	no.	 	 	Award	 	 	Expenditure	 	 	Balance	 
	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$ 	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$ 	-	 	 	 	0	%	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 

 

 

    65

     

     

	Work package 3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Work package 4	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total WP 4	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 
	WP4.1 Research
    batch Ag #3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 4.1	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	WP4.2
    Preclinical POC Ag #3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 4.2	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	WP4.3
    Development & GMP Ag #3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 4.3	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	WP4.4
    Regulatory Ag #3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Consultants	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Other Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	Sub-awards	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL DIRECT COST	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	Indirect Cost (Primary
    Awardee Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	Indirect Cost (Sub-award
    Portion)	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 
	TOTAL
    WP 4.4	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 

 

 

    66

     

     

	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	 	 	 	 	$	-	 	 	$	0.00	 
	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	 	0	%	 	 	 	$	-	 	 	$	-	 	 	$	0.00	 

 

 

    67

     

     

 

	Note
    no.	 	Variance
    notes
	1	 	 
	2	 	 
	3	 	 
	4	 	 
	5	 	 
	6	 	 
	7	 	 
	8	 	 
	9	 	 
	10	 	 
	11	 	 
	12	 	 
	13	 	 
	14	 	 
	15	 	 
	16	 	 
	17	 	 
	18	 	 
	19	 	 
	20	 	 

 

    68

     

    

 

	1.
    Six-Month Projection
	Please describe the
    components of your projected six-month expenditure, commenting on all cost categories.
	 
	2. Personnel
	Please describe whether
    the staff and FTE were needed for the current quarterly period as anticipated, and if they were deployed as expected. (Please
    provide your transaction list demonstrating your actual quarterly Personnel costs).
	 
	3. Travel
	Please describe whether
    planned travel was undertaken as expected during the current quarterly period. Please describe the travel that was undertaken.
    (Please provide your transaction list demonstrating your actual quarterly Travel costs).
	 
	4. Consultants
	Please individually
    list any consultants that were deployed and reimbursed during the current quarterly period, including the number of billable
    units. (Please provide your transaction list demonstrating your actual quarterly Consultant costs).
	 
	5. Equipment &
    Capital Expenditure
	Please describe whether
    equipment items were purchased in line with your projected expenditure for the current quarterly period. (Please provide your
    transaction list demonstrating your actual quarterly Equipment & Capital Expenditure costs).
	 
	6. Other Direct
    Costs
	Please describe whether
    other direct costs were as expected in-line with your projected expenditure for the current quarterly period. (Please provide
    your transaction list demonstrating your actual quarterly Other Direct Costs).

 

    69

     

    

 

	7.
    Sub-awards
	Please individually
    list the sub-awardees that were deployed and reimbursed during the quarterly period. (Please provide your transaction list
    demonstrating your actual quarterly Sub-award costs).
	 
	8. Work-Package
	Please describe your
    confidence that the total remaining Work Package funds per cost category are sufficient to complete the Work Package activities.
    For example, do you expect to incur new or unplanned costs in order to complete the Work Package activities.
	 
	9. Risk
	Please describe any
    potential technical or financial risks that may have an impact on the project’s financial performance.
	 
	10. Non-USD expenditure
	If you have indicated
    non-USD expenditure on the cover letter, please explain which portion of your actual expenditure was incurred in each currency.
	 
	11. Procurement
	During the current
    quarterly period did you procure any goods, services or supplies, or, enagage any subawardee, subcontractors or other third
    parties who were not specifically named in the Work Package budget? If yes, please list the third party name, value and a
    brief description of the goods, services or supplies and describe how you complied with the CEPI Procurement Procedure.

 

    70

     

    

 

 

	 	 	Q1	 	 	Q2	 	 	Q3	 	 	Q4	 	 	Y1
    Total	 	 	Q5	 	 	Q6	 	 	Q7	 	 	Q8	 	 	Year
    2 Total	 	 	Q9	 	 	Q10	 	 	Q11	 	 	Q12	 	 	Year
    3 Total	 	 	Total
    Award	 
	WP1.1
    Research batch Ag #1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 1.1.
    Carry-over Amount from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 1.1 CEPI Biannual
    Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 1.1 Projected 6
    Month Expenditure	 	 	0.00	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 1.1 Retained Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 1.1 Payment Reduction
    (Positive Balance at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 1.1 Biannual Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 1.1 Interest Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.1 Other Gains
    / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP
    1.1 TOTAL CASH AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 1.1 Funds Spent
    on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.1 Funds Spent
    on Indirect Cost (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.1 Funds Spent
    on Indirect Cost (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP
    1.1 Total Expenditure by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP
    1.1 TOTAL BALANCE AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP1.2
    Preclinical POC Ag #1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 1.2 Carry-over Amount
    from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 1.2 CEPI Biannual
    Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 1.2 Projected 6
    Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 1.2 Retained Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 1.2 Payment Reduction
    (Positive Balance at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 1.2 Biannual Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 1.2 Interest Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.2 Other Gains
    / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP
    1.2 TOTAL CASH AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 1.2 Funds Spent
    on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.2 Funds Spent
    on Indirect Cost (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.2 Funds Spent
    on Indirect Cost (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP
    1.2 Total Expenditure by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP
    1.2 TOTAL BALANCE AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 

 

 

    71

     

     

	WP1.3 Regulatory Ag #1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 1.3 Carry-over Amount
    from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 1.3 CEPI Biannual Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 1.3 Projected 6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 1.3 Retained Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 1.3 Payment Reduction (Positive Balance
    at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 1.3 Biannual Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 1.3 Interest Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.3 Other Gains / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.3 TOTAL CASH
    AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 1.3 Funds Spent on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.3 Funds Spent on Indirect Cost
    (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.3 Funds Spent on Indirect Cost
    (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.3 Total Expenditure
    by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 1.3 TOTAL BALANCE
    AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP2.1 Research batch
    Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.1. Carry-over Amount from Prior
    Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 2.1 CEPI Biannual Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.1 Projected 6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 2.1 Retained Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 2.1 Payment Reduction (Positive Balance
    at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 2.1 Biannual Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 2.1 Interest Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.1 Other Gains / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.1 TOTAL CASH
    AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.1 Funds Spent on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.1 Funds Spent on Indirect Cost
    (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.1 Funds Spent on Indirect Cost
    (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.1 Total Expenditure
    by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.1 TOTAL BALANCE
    AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP2.2 Preclinical
    POC Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.2 Carry-over Amount from Prior
    Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 2.2 CEPI Biannual Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.2 Projected 6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 2.2 Retained Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 2.2 Payment Reduction (Positive Balance
    at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 2.2 Biannual Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 2.2 Interest Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.2 Other Gains / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.2 TOTAL CASH
    AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.2 Funds Spent on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.2 Funds Spent on Indirect Cost
    (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.2 Funds Spent on Indirect Cost
    (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.2 Total Expenditure
    by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.2 TOTAL BALANCE
    AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 

 

 

    72

     

     

	WP2.3 Development & GMP Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.3 Carry-over Amount
    from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 2.3 CEPI Biannual Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.3 Projected 6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 2.3 Retained Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 2.3 Payment Reduction (Positive Balance
    at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 2.3 Biannual Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 2.3 Interest Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.3 Other Gains / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.3 TOTAL CASH
    AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.3 Funds Spent on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.3 Funds Spent on Indirect Cost
    (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.3 Funds Spent on Indirect Cost
    (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.3 Total Expenditure
    by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.3 TOTAL BALANCE
    AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP2.4 Regulatory
    Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.4 Carry-over Amount from Prior
    Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 2.4 CEPI Biannual Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.4 Projected 6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 2.4 Retained Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 2.4 Payment Reduction (Positive Balance
    at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 2.4 Biannual Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 2.4 Interest Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.4 Other Gains / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.4 TOTAL CASH
    AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 2.4 Funds Spent on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.4 Funds Spent on Indirect Cost
    (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.4 Funds Spent on Indirect Cost
    (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.4 Total Expenditure
    by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 2.4 TOTAL BALANCE
    AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP3.1 Clinical trial
    Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 3.1 Carry-over Amount from Prior
    Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 3.1 CEPI Biannual Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 3.1 Projected 6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 3.1 Retained Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 3.1 Payment Reduction (Positive Balance
    at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 3.1 Biannual Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 3.1 Interest Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.1 Other Gains / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.1 TOTAL CASH
    AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 3.1 Funds Spent on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.1 Funds Spent on Indirect Cost
    (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.1 Funds Spent on Indirect Cost
    (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.1 Total Expenditure
    by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.1 TOTAL BALANCE
    AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 

 

 

    73

     

     

 

 

	WP3.2
    Regulatory Ag #2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP
    3.2 Carry-over Amount from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 3.2 CEPI Biannual
    Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 3.2 Projected
    6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 3.2 Retained
    Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 3.2 Payment
    Reduction (Positive Balance at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 3.2 Biannual
    Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 3.2 Interest
    Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.2 Other Gains
    / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.2 TOTAL
    CASH AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 3.2 Funds Spent
    on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.2 Funds Spent
    on Indirect Cost (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.2 Funds Spent
    on Indirect Cost (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.2 Total
    Expenditure by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 3.2 TOTAL
    BALANCE AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP4.1
    Research batch Ag #3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.1 Carry-over
    Amount from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 4.1 CEPI Biannual
    Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.1 Projected
    6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 4.1 Retained
    Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 4.1 Payment
    Reduction (Positive Balance at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 4.1 Biannual
    Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 4.1 Interest
    Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.1 Other Gains
    / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.1 TOTAL
    CASH AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.1 Funds Spent
    on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.1 Funds Spent
    on Indirect Cost (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.1 Funds Spent
    on Indirect Cost (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.1 Total
    Expenditure by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.1 TOTAL
    BALANCE AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP4.2
    Preclinical POC Ag #3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.2 Carry-over
    Amount from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 4.2 CEPI Biannual
    Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.2 Projected
    6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 4.2 Retained
    Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 4.2 Payment
    Reduction (Positive Balance at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 4.2 Biannual
    Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 4.2 Interest
    Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.2 Other Gains
    / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.2 TOTAL
    CASH AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.2 Funds Spent
    on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.2 Funds Spent
    on Indirect Cost (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.2 Funds Spent
    on Indirect Cost (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.2 Total
    Expenditure by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.2 TOTAL
    BALANCE AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 

 

    74

     

    

 

	WP4.3
    Development & GMP Ag #3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP
    4.3 Carry-over Amount from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a
                                         	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 4.3 CEPI Biannual
    Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.3 Projected
    6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 4.3 Retained
    Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 4.3 Payment
    Reduction (Positive Balance at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 4.3 Biannual
    Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 4.3 Interest
    Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.3 Other Gains
    / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.3 TOTAL
    CASH AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.3 Funds Spent
    on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.3 Funds Spent
    on Indirect Cost (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.3 Funds Spent
    on Indirect Cost (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.3 Total
    Expenditure by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.3 TOTAL
    BALANCE AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP4.4
    Regulatory Ag #3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.4 Carry-over
    Amount from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 4.4 CEPI Biannual
    Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.4 Projected
    6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 4.4 Retained
    Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 4.4 Payment
    Reduction (Positive Balance at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 4.4 Biannual
    Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 4.4 Interest
    Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.4 Other Gains
    / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.4 TOTAL
    CASH AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 4.4 Funds Spent
    on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.4 Funds Spent
    on Indirect Cost (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.4 Funds Spent
    on Indirect Cost (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.4 Total
    Expenditure by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 4.4 TOTAL
    BALANCE AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP5.1
    Clinical trial Ag #3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 5.1 Carry-over
    Amount from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a
                                         	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 5.1 CEPI Biannual
    Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 5.1 Projected
    6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 5.1 Retained
    Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 5.1 Payment
    Reduction (Positive Balance at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 5.1 Biannual
    Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 5.1 Interest
    Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.1 Other Gains
    / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.1 TOTAL
    CASH AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 5.1 Funds Spent
    on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.1 Funds Spent
    on Indirect Cost (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.1 Funds Spent
    on Indirect Cost (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.1 Total
    Expenditure by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.1 TOTAL
    BALANCE AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 

 

    75

     

    

 

	WP5.2 Regulatory
    Ag#3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenue	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP
    5.2 Carry-over Amount from Prior Period	 	 	 	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	n/a	 
	WP 5.2 CEPI Biannual
    Payment:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 5.2 Projected
    6 Month Expenditure	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 5.2 Retained
    Amount	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 
	WP 5.2 Payment
    Reduction (Positive Balance at Period End Only)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	0.00	 	 	 	n/a	 
	WP 5.2 Biannual
    Payment	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	 	 
	WP 5.2 Interest
    Earned	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.2 Other Gains
    / (Losses)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.2 TOTAL
    CASH AVAILABLE BY PERIOD	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	Expenditure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	WP 5.2 Funds Spent
    on Direct Costs	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.2 Funds Spent
    on Indirect Cost (Primary Awardee Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.2 Funds Spent
    on Indirect Cost (Subaward Portion)	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.2 Total
    Expenditure by Period	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 
	WP 5.2 TOTAL
    BALANCE AT PERIOD END	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 	 	 	0.00	 

 

    76

     

    

 

 

	Asset
    and Equipment Register Template	 
	Organisation:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Address:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Asset/
    Equipment

    No.*	 	 	Asset/Equipment

    Description	 	 	Purchase

    Date	 	 	Purchase

    Price	 	 	Purchase

    Currency	 	 	Location

    (include

    full

    address)	 	 	Pricing

    Class	 	 	Manufacturer,

    Model/Model No, 

    and item serial

    number.	 	 	Warranty
    No. and

    Duration (Years)	 	 	Maintenance

    Requirements	 	 	Supplier
    Details

    (Name, address, registration

    number etc)	 
	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	4	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	5	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	6	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	7	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	8	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	9	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	10	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	TOTAL	 	 	 	 	 	 	 	 	 	 	$	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

(*Equipment
only includes items with a unit cost of at least $5,000 (USD) and a useful life of more than one year)

 

	Pricing Class	 	 	 	 
	Price Type:	 	 	Purchase
    Price:	 
	A	 	 	$5,000
    - $12,799	 
	B	 	 	$12,800
    - $63,999	 
	C	 	 	$64,000
    <	 

 

 

    77

     

     

 

	 	 	 	 	 
	 	 	 	 	 
	Awardee name	 	 	 	Coalition for Epidemic
    Preparedness Innovations, CEPI
	 	 	 	 	Marcus Thranes gate
    2
	Address	 	 	 	0473 OSLO
	 	 	 	 	Norway
	 	 	 	 	Registration number:
    917687811
	 	 	 	 	 
	Reg.no.	 	 	 	 
	 	 	 	 	 
	Subject:	 	Biannual
    payment request	 	 
	 	 	 	 	 
	Your reference	 	 	 	 
	 	 	 	 	 
	CEPI’s reference	 	INCU1901	 	 
	 	 	 	 	 
	Payment request number	 	 	 	 
	 	 	 	 	 
	Start date, 6 month
    payment period	 	 	 	 
	 	 	 	 	 
	End date, 6 month payment
    period	 	 	 	 
	 	 	 	 	 
	Is report for previous
    biannual period enclosed?	 	 	 	If no, please explain
    why:
	 	 	 	 	 
	A. Total projected
    expenditure this payment period	 	 	 	 
	 	 	 	 	 
	For reference: CEPI
    retainer % applied to projected expenditure	 	N/A	 	 
	 	 	 	 	 
	B.
    Total retained, this payment period	 	$	-	 	 
	 	 	 	 	 
	C. Interest earned
    in previous payment period	 	 	 	 
	 	 	 	 	 
	D. Available cash balance
    (from previous reporting period)	 	 	 	 
	 	 	 	 	 
	E. Total payment
    request	 	$	-	 	 
	 	 	 	 	 
	Awardee Bank Account
    Details for Receipt of CEPI Funds	 	 	 	 
	Account holder	 	 	 	 
	Name of bank	 	 	 	 
	Branch address	 	 	 	 
	IBAN	 	 	 	 
	BIC/SWIFT	 	 	 	 
	 	 	 	 	 
	I hereby declare that to the best of my knowledge all
    information provided in this payment request is full, reliable and true.
	 	 	 	 	 
	 	 	 	 	 
	Place and date	 	 	 	 	Signature authorised
    representative
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	Printed name and title
	 	 	 	 	 

 

 

    78

     

     

 

SCHEDULE
9

 

QUARTERLY
REPORT TEMPLATE

 

    79

     

    

 

CEPI
Quarterly Report

 

CUREVAC
AG

 

From ...... to ......

 

Executive Summary

 

(Please provide a
short summary of progress and/or issues encountered over the last three months-<300 words).

 

Quarterly Report

 

(Please amalgamate
the previous three monthly reports into two slides as shown below).

 

	Current
    Project Status	Next
    steps
	 	·
     Please
    describe the preparations required for the next steps in the project here
	·
    WP-X.1
	·
    <short description
    of work-package and status>	 
	 	 
	·
    WP-X.2	 
	·
    < short description
    of work-package and status >	 
	 	 
	·
    WP-X.3	Next
    Milestone/Stage Gate
	·
    < short description
    of work-package and status >	·
     Please
    include milestones and/or Stage Gates due within the next 30 days
	 	 
	 	Challenges
	 	·
     Review
    the risk register here, highlighting any new issues in particular or the status of ongoing problems

 

		·	Please
                                         list progress towards the next Milestone, Deliverable or Stage Gate due within the
                                         next month

 

	WBS	Milestone,
    Deliverable or Stage Gate	Target

    Completion Date	Actual

                                         Completion

                                         Date
	Status	
	 	 	Date	 	
	 	 	Date	 	
	 	 	Date	 	
	 	 	 	 	 
	·
    If any tasks are causing concern
    please explain any remedial actions and update the Risk Registry accordingly
	 
	WBS	Task
    description	Issue
    plus remedial action
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 	 	 

 

Progress

 

    80

     

    

 

(Please insert progress
chart from latest monthly report.)

 

 

 

(Please update the
following table based on activities which have been completed within the last six months).

 

	Milestones/Deliverables	Activity
	WP
    X.Y	Milestone
    achieved
	 	 
	Stage
    Gate	 
	WP
    X.Y	Stage
    Gate achieved
	 	 

 

    81

     

    

 

Communication

 

(Please update the
following table with the communication activities from the quarter and the planned ones for the next three months).

 

	Past
    three months	 	Next
    three months	 
	Type
    of	Who	When	Type
    of	Who	When
	communication	 	 	communication	 	 
		 	 		 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

 

Intellectual Property

 

(Please fill in the
table below. This is a reflection of the obligations outlined in the agreed Partnership Agreement)

 

During the previous 3
months;

 

	Have
    you or any subawardee generated any of the following? If yes, please describe below.
	New
    or novel scientific or test data? Including clinical data, CMC data, pharmacological data or toxicological data?	New
    or novel invention, work or discovery? Including concepts, data, designs, formulae, methods, models, assays, procedures, processes,
    specifications or algorithms?
	(Please
                                         insert details here)

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 
	(Please
    insert details here)
	 	 
	If
    you or any subawardee has generated any novel invention, work or discovery, please describe if you have or if will you seek
    intellectual protection for a registered patent, design right, trade-mark, trade-name, database right, copyright or other
    right subsisting in any part of the world?
	(Please
                                         insert details here)

                                                                                 

                                                                                 

                                                                                 

                                                                                 

                                                                                 

	 
	Have
    you or any subawardee made any formal submissions to any Regulatory Authority relating to the development, manufacture or
    marketing of any product, results, foreground intellectual property or other outputs from the CEPI project? If yes, please
    describe below and provide copies of all minutes, communications and other submission documentation.
	(Please
                                         insert details here)

                                                                                 

                                                                                 

                                                                                 

 

    82

     

    

 

	During
    the next 3 months, do you or any subawardee intend to publish or disseminate any foreground intellectual property, results
    or data from the CEPI project? If yes, please describe:
	The
    foreground intellectual property, results or data that you wish to publish or disseminate?	The
    authors who will be named?	How
    you will comply with CEPI’s open access requirements set out in the Partnering Agreement and CEPI’s Open Access
    Policy ?
	(Please
                                         insert details here)

                                                                                 

                                                                                 

                                                                                 
	(Please
    insert details here)	(Please
    insert details here)
	 	 	 

 

	During
    the next 3 months, do you intend to deploy, use or exploit any foreground intellectual property, results or outputs from the
    CEPI project outside of the CEPI project? If yes, please describe below.
	Your
    proposed or intended further use or exploitation?	If
    the use or exploitation will occur in the Field of the CEPI project and/or in an Affect Territory?	If
    the use or exploitation is for the purpose of Development or Marketing activities?	If
    the use or exploitation is for the purpose of generating commercial revenue
	(Please
                                         insert details here)

                                                                                 

                                                                                 

                                                                                 
	(Please
    insert details here)	(Please
    insert details here)	(Please
    insert details here)

 

Forecast

 

(Please provide a
forecast for the next six months of milestones/deliverables and any Stage Gates due. Please explain briefly the main activities
which will need to be completed).

 

	Milestones/Deliverables	Activity
	WP
    X.Y	Milestone/Deliverable(s)
    and date due
	 	 
	Stage
    Gate	 
	WP
    X.Y	Stage
    Gate(s) and due date
	 	 
	Intellectual
    Property	 
	Area
    covered	Please
    outline any proposed filing within the next 6 months

 

    83

     

    

 

Change Control

 

(Please describe any
agreed changes to activities of the project and impact the impact that this may have on timelines. Insert the date that was originally
targeted for completion of the activity, and revised date.).

 

	Function	Change	Impact	Initial	Revised
	 	 	 	date	date
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

Planning

 

(Please attach a link
to the Gantt chart with progress bars updated. This should be stored on your secure server. Please copy the original and rename
it with the appropriate time period. For example. Project_Plan_Jan19_Mar19).

 

Risk Register

 

(Please update the
Risk Register and attach a link to its location on your secure server. Please copy the original and rename it with the appropriate
time period. For example. Risk_Register_Jan19_Mar19).

 

    84

     

    

 

SCHEDULE 10

 

CEPI POLICIES

 

[*****]

 

    85

     

    

 

SCHEDULE 11

 

TEAM CHARTER

 

[*****] 

 

    86

     

    

 

SCHEDULE 12

 

DISCLOSURE LETTER

[*****]

 

    87

     

    

 

SCHEDULE 13

 

PARTNER FUNDER REQUIREMENTS

 

[*****]

 

    88Exhibit 10.12

 

Confidential

 

REDACTED

Certain
identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material
and (ii) would likely cause competitive harm if publicly disclosed.

 

EXECUTION COPY

 

SIDE AGREEMENT AND AMENDMENT NUMBER ONE

 

to the

 

DEVELOPMENT AND OPTION AGREEMENT

 

THIS SIDE AGREEMENT
AND AMENDMENT (“Amendment Agreement”) to the DEVELOPMENT AND OPTION AGREEMENT is entered into effective as of
December I, 2016 (the “Amendment One Date”), by and between ACUITAS THERAPEUTICS INC., with offices at
2714 West 31st Avenue, Vancouver, British Columbia, V6L 2Al, Canada (“Acuitas”), and CUREVAC AG,
a company incorporated in Germany whose registered office is at Paul-Ehrlich-Straf3e 15, 72076 Tübingen, Germany (“CureVac”).

 

RECITALS

 

WHEREAS, Acuitas
and CureVac entered into that certain Development and Option Agreement effective April 29th 2016 (the “D&O Agreement”)
relating to the evaluation of and options to licence Acuitas LNP Technology for the research, development, manufacture and/or commercialisation
of products incorporating Acuitas LNP Technology and CureVac Technology;

 

WHEREAS, both
Acuitas and CureVac desire to include in the Work Plan the evaluation of Acuitas LNP Technology together with CureVac Technology
relating to Gene Editing; and

 

WHEREAS, to
enable the prompt commencement of such evaluation both Acuitas and CureVac desire to agree to certain side terms and conditions
to, and to make certain amendments to the provisions of, the D&O Agreement so that a limited such evaluation may be commenced.

 

NOW, THEREFORE,
in consideration of the mutual covenants and representations contained herein, and for other good and valuable consideration, the
amount and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

AGREEMENT

 

		1.	Definitions.

 

		1.1.	“DNA Sequence” means, for the purpose of this Amendment Agreement only, any
sequence of DNA [*****] as such DNA Sequence(s) and Gene Target(s) are
specified in Exhibit 3.1 or are subsequently reserved in accordance with Paragraph 2.3 hereof.

 

		1.2.	“Gene Target”
                                         means, for the purpose of this Amendment Agreement only [*****] and/or pre-defined variants
                                         thereof, as such coding or non-coding sequence(s) and/or variant(s) are specified
                                         in Exhibit 3.1 or are subsequently reserved in accordance with Paragraph
                                         2.3 hereof.

 

     

     

    

 

Confidential

 

		1.3.	“DNA Editing Protein” means, for the purpose of this Amendment Agreement only,
a Target encoded by an mRNA that upon delivery to a cell or micro-organism is intended to Gene Edit a human, animal, microorganism
or virus coding or non-coding sequence within the genome of the human or animal cell, or microorganism or virus.

 

		1.4.	“Gene Edit” means, for the purpose of this Amendment Agreement only, to correct,
modify, insert, delete, activate, inactivate or repair a coding or non-coding sequence within the genome of a human or animal cell,
or microorganism or virus; and “Gene Editing” has the corresponding meaning.

 

		1.5.	“Guide RNA” means, for the purpose of this Amendment Agreement only,  [*****]

 

		1.6.	The definition of “Approved Partner” in Section 1.11 of the D&O Agreement
shall be replaced in its entirety by the following:

 

“1.11     “Approved
Partner” means with respect to any Third Party to whom CureVac wishes to disclose Acuitas Confidential Information or
transfer Acuitas LNP Technology or Materials provided by Acuitas to CureVac: (i) any Third Party licensee of CureVac Technology;
(ii) any Third Party providing services set forth in the Work Plan to CureVac; or (iii) [*****].

 

		1.7.	All capitalised terms used in this Amendment Agreement and not otherwise defined in this Amendment
Agreement have the meanings assigned them in the D&O Agreement.

 

		2.	Target Reservation.

 

		2.1.	On the Amendment One Date, the DNA Editing Protein [*****] on the Reserved Target List as a non-exclusive
Target.

 

		2.2.	Until the conclusion of the Gene Editing Work Plan, CureVac hereby covenants to not submit any
Target Notice for any other DNA Editing Protein.

 

		2.3.	In addition to the DNA Editing Protein Target, for the purpose of this Amendment Agreement only
CureVac may non-exclusively reserve up to [*****] Gene Targets, and optionally up to [*****] DNA Sequences for each Gene Target,
in each case at [*****]. The DNA Editing Protein Target counts as a single Reserved Target, however, [*****] available to CureVac under Article 4
of the D&O Agreement. CureVac will however be required to submit to the Escrow Agent for clearance and reservation all Gene
Targets and DNA Sequences in accordance with Gene Target/DNA Sequence preclearance and reservation requirements analogous to those
set forth for Targets in Sections 4.2 of the D&O Agreement.

 

		3.	Program extension and Work-Plan for Gene Editing.

 

		3.1.	The Parties hereby append Exhibit 3.1 (the “Gene Editing Work Plan”)
as attached to this Amendment Agreement to the Work-Plan.

 

     

     

    

 

Confidential

 

		3.2.	On the Amendment One Date, the Gene Editing Work Plan relates: (i) only to the use of [*****]
as a DNA Editing Protein; and (ii) only to the Gene Targets and (iii) only to the DNA Sequences, such Gene Targets and
DNA Sequences having been pre-cleared by the Escrow Agent by a mechanism analogous to that set forth in Section 4.2 of the
D&O Agreement.

 

		3.3.	Acuitas hereby acknowledges that certain parts of the Gene Editing Work Plan include the
                                                                  evaluation of: (i) LNPs containing [*****] mRNA Constructs intended to express the DNA Editing Protein [*****] without
                                                                  containing [*****] Guide RNA(s), and/or without containing [*****] DNA Sequences; and (ii) separate LNPs containing
                                                                  [*****] Guide RNA(s), and/or containing [*****] DNA Sequences, in each case without containing said mRNA Construct(s),
                                                                  although the LNPs of (ii) are intended to be evaluated only in connection with those of (i).

 

		3.4.	Until the conclusion of the Gene Editing Work Plan, CureVac hereby covenants to neither: (i) submit
any additional DNA Editing Proteins for pre-clearance by the Escrow Agent; nor (ii) change the scope of the Gene Editing Work
Plan beyond that stated in (i) to (iii) of Paragraph 3.2 hereof, without obtaining the prior consent of Acuitas, such
consent not to be unreasonably withheld or conditioned.

 

		3.5.	For the period during which [*****] is on the Reserved Target List, Acuitas hereby covenants not
to provide any Third Party with any exclusive right, or option to obtain any exclusive right, under the Acuitas LNP Technology
that would prevent CureVac from taking non-exclusive rights to any Gene Target or DNA Sequence which has been reserved in accordance
with Section 2.3.

 

		3.6.	The second to last sentence of Section 3.4 of the D&O Agreement shall be replaced in its
entity by the following:

 

“CureVac shall use commercially
reasonable efforts to obtain the foregoing assignment for Approved Partners, and if CureVac is unable to obtain such assignment,
CureVac shall obtain: (x) [*****]; or (y) [*****], or seek to protect any such Know-How by any other form of intellectual property, without prior written
permission from CureVac. CureVac shall not give such permission without the prior consent of Acuitas, such consent not to be unreasonably
withheld or conditioned.”

 

		4.	Licensed Product Option for Gene Editing. Acuitas and CureVac shall discuss and negotiate
in good faith, for the duration of the Gene Editing Work Plan, on the terms and conditions under which the D&O Agreement (and
associated License Agreements) will be amended to encompass Licensed Products useful for Gene Editing for the purposes of Article 5
CureVac License Options; it being hereby agreed between the Parties that, with reference to the D&O Agreement (and associated
License Agreements) on the Amendment One Date, the financial terms (including reservation costs, option exercise fees, milestones
and royalties applied to any such Licensed Products useful for Gene Editing will be consistent with the corresponding financial
terms already provided for in the D&O Agreement (and associated License Agreements) provided, that: (i) [*****] (ii) [*****] will be applied for Guide RNAs (with the applicability of such reservation
costs for multiple Gene Targets to be discussed during such negotiations); and (iii) each DNA Editing Protein as a Target
will count as a single Reserved Target, [*****] Reserved Targets available to CureVac under Article 4 of the D&O Agreement. For clarity, the terms “DNA
Sequence” and “Gene Target” (and correspondingly, “Guide RNA”), as used in this Paragraph 4, will
not be limited to those sequences specified in Exhibit 3. I hereof, but will be redefined by such amendment based on the definitions
herein.

 

     

     

    

 

Confidential

 

		5.	Amendment of Section 3.5(c) of the D&O Agreement.

 

		5.1.	Section 3.5(c) of the D&O Agreement is hereby amended to add the following at the
end of such section:

 

“Acuitas shall not be required
to maintain the licenses to In-Licensed Technology with respect to which CureVac shall not have exercised the option set forth
in this subsection (c). Accordingly, Acuitas is free to enter into new licenses and modify or terminate existing licenses to any
In-Licensed Technology until such time as it is licensed to CureVac; provided, that Acuitas has given CureVac at least [*****]
days’ prior written notice of any modification or termination of any existing license to any In-Licensed Technology, such
notice to specify the In-Licensed Technology to be modified or terminated. The parties acknowledge that any exercise of a sublicense
to any In-Licensed Technology must be in accordance with the terms of Acuitas’ main Third Party license agreement.”

 

		5.2.	Acuitas represents and warrants that, on the Amendment One Date, it has no intent to immediately
modify or terminate any existing license to any In-Licensed Technology to which CureVac has the option under Section 3.5(c) of
the D&O Agreement.

 

		6.	Miscellaneous.

 

		6.1.	Except as expressly stated in this Amendment Agreement, the D&O Agreement remains unchanged
and in full force and effect.

 

		6.2.	The provisions of ARTICLE IO of the D&O Agreement shall be applied by analogy to this
Amendment Agreement.

 

     

     

    

 

IN WITNESS
WHEREOF, the Parties have caused Amendment Agreement to be executed by their respective duly authorised officers as of
the Amendment One Date.

 

	CureVac AG	 
	 	 
	By:	/s/ Dr. Florian von der Mülbe	 /s/ Pierre Kemula	 
	Name:	Dr. Florian von der Mülbe	 Pierre Kemula	 
	Title:	Chief Operating Officer	 Chief Financial Officer	 

 

	CureVac AG	 
	 	 
	By:	/s/ Thomas Madden	 
	Name:	Thomas Madden	 
	Title:	President and CEP	 

 

     

     

    

 

Confidential

 

EXHIBIT 3.1: Gene Editing Work
Plan

 

[*****]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]